<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">iScience</journal-id><journal-id journal-id-type="iso-abbrev">iScience</journal-id><journal-title-group><journal-title>iScience</journal-title></journal-title-group><issn pub-type="epub">2589-0042</issn><publisher><publisher-name>The Author(s).</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7524535</article-id><article-id pub-id-type="pii">S2589-0042(20)30823-3</article-id><article-id pub-id-type="doi">10.1016/j.isci.2020.101631</article-id><article-id pub-id-type="publisher-id">101631</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Burtscher</surname><given-names>Johannes</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Cappellano</surname><given-names>Giuseppe</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Omori</surname><given-names>Akiko</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Koshiba</surname><given-names>Takumi</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Millet</surname><given-names>Gr&#x000e9;goire P.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Institute of Sport Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland</aff><aff id="aff2"><label>2</label>Department of Biomedical Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland</aff><aff id="aff3"><label>3</label>Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases- IRCAD, Universit&#x000e0; del Piemonte Orientale, 28100 Novara, Italy</aff><aff id="aff4"><label>4</label>Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Universit&#x000e0; del Piemonte Orientale, 28100 Novara, Italy</aff><aff id="aff5"><label>5</label>Department of Biology, University of Padova, 35121 Padova, Italy</aff><aff id="aff6"><label>6</label>Veneto Institute of Molecular Medicine, 35129 Padova, Italy</aff><aff id="aff7"><label>7</label>Department of Chemistry, Faculty of Science, Fukuoka University, 814-0180 Fukuoka, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author</corresp></author-notes><pub-date pub-type="pmc-release"><day>29</day><month>9</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>23</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2020</year></pub-date><volume>23</volume><issue>10</issue><fpage>101631</fpage><lpage>101631</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>The pathophysiology, immune reaction, and differential vulnerability of different population groups and viral host immune system evasion strategies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not yet well understood. Here, we reviewed the multitude of known strategies of coronaviruses and other viruses to usurp mitochondria-associated mechanisms involved in the host innate immune response and put them in context with the current knowledge on SARS-CoV-2. We argue that maintenance of mitochondrial integrity is essential for adequate innate immune system responses and to blunt mitochondrial modulation by SARS-CoV-2. Mitochondrial health thus may determine differential vulnerabilities to SARS-CoV-2 infection rendering markers of mitochondrial functions promising potential biomarkers for SARS-CoV-2 infection risk and severity of outcome. Current knowledge gaps on our understanding of mitochondrial involvement in SARS-CoV-2 infection, lifestyle, and pharmacological strategies to improve mitochondrial integrity and potential reciprocal interactions with chronic and age-related diseases, e.g., Parkinson disease, are pointed out.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1_lrg"/></fig></abstract><abstract abstract-type="teaser" id="abs0020"><p>Immunology; Virology; Cell Biology</p></abstract><kwd-group id="kwrds0010"><title>Subject Areas</title><kwd>Immunology</kwd><kwd>Virology</kwd><kwd>Cell Biology</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>SARS-CoV-2 Biology: an Equation&#x000a0;with Many Unknowns</title><p id="p0010">The variability of individual vulnerability and regional mortality rates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the ongoing coronavirus disease (COVID-19) pandemic, is poorly understood. Although it is clear that age and pre-existing morbidities (<xref rid="bib119" ref-type="bibr">Wang et&#x000a0;al., 2020</xref>), such as cardiovascular and respiratory diseases, represent major risk factors, mechanistic explanations are lacking. In particular, it remains enigmatic, why sporadic severe disease progression may occur after SARS-CoV-2 infection in young individuals apparently without risk factors. Elucidating the variability in vulnerability, derivation of appropriate biomarkers, and the identification of efficient treatment strategies require thorough understanding of the pathophysiology and immune responses following SARS-CoV-2 infection.</p><p id="p0015">Here we discuss how the cellular innate immune system of an infected host organism fighting viral infection strongly relies on host mitochondria. Viruses commonly manipulate host cells by infiltrating cellular, including mitochondria-mediated, defense mechanisms, leading to an inadequate host immune response that may promote adverse disease outcomes. Given the fast development of the COVID-19 pandemic and thus the only recently launched research efforts on SARS-CoV-2, knowledge on SARS-CoV-2 biology and pathophysiology in humans is still limited. However, the SARS-CoV-2 genome shares 79% with the genome of SARS-CoV (<xref rid="bib23" ref-type="bibr">Coronaviridae Study Group, 2020</xref>), which caused the SARS epidemic in 2002. Building on research on other RNA viruses, in particular SARS-CoV, we integrate emerging evidence on the roles of mitochondria in the innate immune reaction to SARS-CoV-2 infection; how SARS-CoV-2 may evade host immune defense mechanisms by hijacking mitochondrial pathways, as recently suggested (<xref rid="bib101" ref-type="bibr">Singh et&#x000a0;al., 2020</xref>); and how dysfunctional mitochondria could contribute to severe disease progression. For these comparisons it is important to stress the substantial differences in SARS versus COVID-19 epidemiology and symptomatology (<xref rid="bib30" ref-type="bibr">Fani et&#x000a0;al., 2020</xref>; <xref rid="bib86" ref-type="bibr">Petersen et&#x000a0;al., 2020</xref>). A direct comparison of disease pathogenesis after infection with Middle East respiratory syndrome (MERS) CoV and SARS-CoV-2 in a non-human primate model compared with historical SARS-CoV infections has been recently published (<xref rid="bib89" ref-type="bibr">Rockx et&#x000a0;al., 2020</xref>).</p><p id="p0020">We will conclude by highlighting the importance and suggesting promising therapeutic avenues of enhancing mitochondrial functions for an efficient innate immune response.</p></sec><sec id="sec2"><title>SARS-CoV-2 Infection</title><p id="p0025">Cells infected by SARS-CoV, and most likely also by SARS-CoV-2 (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>), are mainly epithelial cells, alveolar epithelial cells, vascular endothelial cells, and macrophages in the lung. In this review we focus on the cellular innate immune response in these primarily infected cells from a mitochondrial perspective. Infection of a number of other cells, including specialized immune cells, has also been described for SARS-CoV (<xref rid="bib114" ref-type="bibr">Tiku et&#x000a0;al., 2020</xref>).</p><p id="p0030">Upon attaching of the virus to the cell surface via angiotensin-converting enzyme 2 (ACE2) and cleavage of the viral spike protein by proteases like transmembrane protease, serine 2 (TMPRSS2) that enables fusion of the virus with the cell membrane, SARS-CoV-2 enters cells by endocytosis (<xref rid="bib7" ref-type="bibr">Azkur et&#x000a0;al., 2020</xref>). The resulting activation of different viral detection systems and innate immune responses of the host cells (<xref rid="bib7" ref-type="bibr">Azkur et&#x000a0;al., 2020</xref>) and the immunopathology of SARS-CoV-2 infection (<xref rid="bib117" ref-type="bibr">Vabret et&#x000a0;al., 2020</xref>) have recently been summarized.</p><p id="p0035">An incubation period of 4&#x02013;5&#x000a0;days usually precedes symptoms of SARS-CoV-2 infection. The peak of viral load is reached after another 5&#x02013;6&#x000a0;days (<xref rid="bib112" ref-type="bibr">Tay et&#x000a0;al., 2020</xref>). In the case of an efficient immune response rapid inactivation of SARS-CoV-2, clearance of infected cells, and the induction of an adequate immune response halt lung vascular damage and adverse disease progression (<xref rid="bib112" ref-type="bibr">Tay et&#x000a0;al., 2020</xref>). Conversely, infection of airway epithelial cells by SARS-CoVs may induce pronounced pyroptosis, a type of cell death associated with a strong inflammatory response (<xref rid="bib21" ref-type="bibr">Cookson and Brennan, 2001</xref>). This has been demonstrated to be triggered in human alveolar epithelial cells (<xref rid="bib131" ref-type="bibr">Yue et&#x000a0;al., 2018</xref>) and macrophages by the SARS-CoV 3a protein (<xref rid="bib17" ref-type="bibr">Chen et&#x000a0;al., 2019</xref>) and likely also happens in SARS-CoV-2 (<xref rid="bib112" ref-type="bibr">Tay et&#x000a0;al., 2020</xref>). Pyroptosis may result in substantial vascular leakage and release of cytokines and chemokines, attracting monocytes and T&#x000a0;cells to the site of injury or inflammation. Direct viral damage can thus be intensified by high levels of proteases and oxidative stress, an integral factor in COVID-19 progression (<xref rid="bib25" ref-type="bibr">Delgado-Roche and Mesta, 2020</xref>), caused by the host defense. SARS-CoV-2 infection is characterized by an inappropriate cytokine host response: a relatively low induction of type I and III interferons blunt the anti-viral host defense and is paralleled by a high induction of chemokines and interleukin (IL)-6 (<xref rid="bib11" ref-type="bibr">Blanco-Melo et&#x000a0;al., 2020</xref>), similar to what has been reported for SARS-CoV infection. Damage to the airways and the resulting inflammatory host response may in turn contribute to the development of symptoms resembling acute respiratory distress syndrome (ARDS). Characteristic diffuse alveolar damage, pulmonary edema, and occasional hyaline membranes impair pulmonary gas exchange and may cause hypoxemia (reduced arterial oxygen pressure) and breathing difficulties. Direct respiratory failure or systemic cytokine-storm-mediated sepsis (including, for example, death from circulatory failure) may ensue, both conditions representing common causes of COVID-19-related death (<xref rid="bib90" ref-type="bibr">Ruan et&#x000a0;al., 2020</xref>).</p></sec><sec id="sec3"><title>The Role of Mitochondria in the Innate Immune System</title><p id="p0040">Innate immune responses are triggered by the activation of pattern recognition receptors, which non-specifically recognize pathogens via pathogen-associated molecular patterns or signals from damaged cells via damage-associated molecular patterns (DAMPs). In response to tissue injury, affected cells drive the recruitment of specialized innate immune cells, which in turn activate the specific adaptive immune response and trigger the production of molecules needed for inflammation and regeneration/repair of injured tissue. It is becoming increasingly clear that mitochondria are fundamentally involved in the mammalian innate immune system (<xref rid="bib8" ref-type="bibr">Banoth and Cassel, 2018</xref>; <xref rid="bib121" ref-type="bibr">Weinberg et&#x000a0;al., 2015</xref>). Mitochondria are most commonly associated with energy production by oxidative phosphorylation, but they are also involved in a myriad of other functions, such as ion homeostasis, cellular signaling, differentiation, and cell death/survival.</p><p id="p0045">Beside mitochondrial reactive oxygen species (ROS) (mtROS)-based involvement in immunity, mitochondrial participation in antiviral defense is now well established (<xref rid="bib123" ref-type="bibr">West et&#x000a0;al., 2011</xref>). Mitochondria play integral roles in anti-viral host response signaling upon infection, and they can activate the innate immune system upon cellular damage via mitochondrial DAMPs. Importantly, SARS-CoV proteins manipulate mitochondrial mechanisms to evade the host immune response and may alter mitochondrial functions leading to enhanced ROS production, perturbed signaling, and blunted antiviral defenses of the host organism.</p><p id="p0050">The following sections summarize the mitochondrial involvement in the innate immune system after infection with RNA viruses and specifically with SARS-CoVs.</p><sec id="sec3.1"><title>Mitochondrial Antiviral Signaling: The RLR Signaling Pathway</title><p id="p0055">The mitochondrial membrane-anchored mitochondrial anti-viral signaling protein MAVS is an essential component of the cellular anti-viral defense system (<xref rid="bib123" ref-type="bibr">West et&#x000a0;al., 2011</xref>). Viruses in the cytoplasm can be detected by retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), including RIG-I and melanoma differentiation-associated gene 5 (MDA5) (<xref rid="bib9" ref-type="bibr">Belgnaoui et&#x000a0;al., 2011</xref>). RLRs activate MAVS, which upon activation forms oligomers in a prion-like manner (<xref rid="bib46" ref-type="bibr">Hou et&#x000a0;al., 2011</xref>). MAVS then recruits a number of downstream signaling effectors, including the E3 ligases tumor necrosis factor receptor-associated factors 3 and 6 (TRAF3 and TRAF6) leading to antiviral defense by the induction of nuclear factor kappa light chain enhancer of activated B cell (NF-&#x003ba;B) and type I interferons via interferon regulatory factors (IRFs). Formation of the MAVS complex (&#x0201c;MAVS signalosome&#x0201d;) is mediated by translocases of the outer mitochondrial membrane 70 (TOM70) and 20 (TOM20) and leads to activation of TANK-binding kinase 1 (TBK1) and phosphorylation of IRF-3. IRF-3 then associates with the cytosolic chaperone heat shock protein 90 (HSP90) to robustly activate an anti-viral response. Dysfunctional MAVS or TOM70 (e.g., due to mislocalization or low protein levels) impair the antiviral host defense. On the other hand, overexpression of TOM70 (<xref rid="bib123" ref-type="bibr">West et&#x000a0;al., 2011</xref>), or increase in the activity of MAVS (<xref rid="bib107" ref-type="bibr">Song et&#x000a0;al., 2019</xref>), boosts the cellular antiviral defenses. MAVS is thought to be tethered to the inner mitochondrial membrane by the proteins prohibitin 1 and 2 (PHB1 and PHB2), which therefore also might play important roles in the regulation of mitochondrial anti-viral innate immunity (<xref rid="bib128" ref-type="bibr">Yoshinaka et&#x000a0;al., 2019</xref>).</p><p id="p0060">The MAVS pathway is preferentially targeted by viruses. For example, the hepatitis C virus serine-protease NS3/4A and the 3ABC protease of the hepatitis A virus cleave MAVS to dissociate it from its outer mitochondrial membrane base, resulting in inhibition of the pathway and thus reducing the cellular capacity to induce antiviral responses (<xref rid="bib66" ref-type="bibr">Li et&#x000a0;al., 2005</xref>; <xref rid="bib125" ref-type="bibr">Yang et&#x000a0;al., 2007</xref>). Similarly, influenza virus protein PB1-F2 was shown to bind and impair MAVS (<xref rid="bib118" ref-type="bibr">Varga et&#x000a0;al., 2012</xref>), thereby blunting the interferon response.</p></sec><sec id="sec3.2"><title>Mitochondrial Dynamics in the Innate Immune System</title><p id="p0065">Cell metabolism in general (<xref rid="bib132" ref-type="bibr">Zas&#x00142;ona and O'Neill, 2020</xref>) and mitochondria in specific play integral roles in the host defense of many diseases, including viral infections.</p><p id="p0070">Changes of metabolic or physiological conditions, such as infection (<xref rid="bib8" ref-type="bibr">Banoth and Cassel, 2018</xref>), induce morphological changes (&#x0201c;mitochondrial dynamics&#x0201d;) of mitochondria with functional consequences importantly affecting the innate immune response. Mitochondria transition from shorter to longer organelles (fusion) and the other way around (fission) by means of factors regulating mitochondrial dynamics, including the fusion factors mitofusins 1 and 2 (MFN1 and MFN2), optic atrophy 1 (OPA1) and the fission factor dynamin-related protein-1 (DRP1). These mechanisms and consequences are described excellently and in detail elsewhere (<xref rid="bib38" ref-type="bibr">Giacomello et&#x000a0;al., 2020</xref>; <xref rid="bib85" ref-type="bibr">Pernas and Scorrano, 2016</xref>), but due to the high relevance of the present work are briefly outlined also here. Mitochondria are enclosed by two membranes, the inner and outer mitochondrial membranes (IMM and OMM, respectively). The OMM enzymes MFN1 and MFN2 are effectors for the fusion of the OMM, which is followed by OPA1-mediated IMM fusion. OPA1 itself is regulated by the metalloproteases YME1L and OMA1.</p><p id="p0075">Mitochondrial fission is mediated primarily by DRP1, which is recruited from the cytosol to the fission site. There it forms ring-like oligomers around the mitochondrion and induces mitochondria division by GTP hydrolysis-mediated DRP1 constriction. The recruitment of DRP1 to mitochondria is believed to be mediated by adaptor proteins, including mitochondrial fission factor (MFF), fission 1 (FIS1), and the mitochondrial dynamics proteins of 49 and 51&#x000a0;kDa (MiD49 and MiD51). Their functions are not completely understood, and in particular MiD49 and MiD51 may affect both fission and fusion depending on the cellular conditions (<xref rid="bib85" ref-type="bibr">Pernas and Scorrano, 2016</xref>). DRP1-mediated fission is strongly dependent on posttranslational modifications and can be induced by elevated cytosolic Ca<sup>2+</sup> levels that lead to the calcineurin-dependent de-phosphorylation of DRP1 Ser637 (<xref rid="bib24" ref-type="bibr">Cribbs and Strack, 2007</xref>). Conversely, phosphorylation of DRP1 Ser616 (position reflecting the human DRP1) promotes fission (<xref rid="bib109" ref-type="bibr">Taguchi et&#x000a0;al., 2007</xref>).</p><p id="p0080">Fusion is promoted in conditions of nutrient scarcity and is thought to boost mitochondrial bioenergetics efficiency, whereas fission is favored when nutrients are not limited and results in increased nutrient storage, but conversely reduced bioenergetics efficiency (<xref rid="bib94" ref-type="bibr">Schrepfer and Scorrano, 2016</xref>). Mitochondrial fusion furthermore enables the exchange of mtDNA, metabolites, proteins, and lipids (<xref rid="bib85" ref-type="bibr">Pernas and Scorrano, 2016</xref>), whereas fission is not only associated with increased ROS production but also facilitates mitochondrial quality control (mitophagy) and mitochondrial distribution, for example, to match local energy demands (<xref rid="bib38" ref-type="bibr">Giacomello et&#x000a0;al., 2020</xref>; <xref rid="bib45" ref-type="bibr">Horn et&#x000a0;al., 2020</xref>).</p><p id="p0085">Mitochondrial dynamics are highly affected and in some cases compromised by viral infections, which affects host responses. These mechanisms have been reviewed specifically from that perspective (<xref rid="bib53" ref-type="bibr">Khan et&#x000a0;al., 2015</xref>; <xref rid="bib55" ref-type="bibr">Kim et&#x000a0;al., 2018</xref>). Viral infections may result in strongly elongated mitochondria potentially enhancing antiviral signaling (<xref rid="bib14" ref-type="bibr">Castanier et&#x000a0;al., 2010</xref>; <xref rid="bib81" ref-type="bibr">Onoguchi et&#x000a0;al., 2010</xref>). Several factors regulating mitochondrial dynamics appear to regulate mitochondrial antiviral signaling. Pro-fusion protein MFN2 levels have been shown to regulate MAVS efficiency, i.e., high levels of MFN2 impair MAVS by changing its active conformation (<xref rid="bib93" ref-type="bibr">Sasaki et&#x000a0;al., 2013</xref>), whereas MFN2 depletion enhances MAVS activity (<xref rid="bib127" ref-type="bibr">Yasukawa et&#x000a0;al., 2009</xref>). Conversely, reductions of MFN1 and OPA1 inhibited MAVS-mediated induction of NF-&#x003ba;B and IRF3 (<xref rid="bib14" ref-type="bibr">Castanier et&#x000a0;al., 2010</xref>). MFN2 furthermore has been reported to be involved in the Nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation (<xref rid="bib48" ref-type="bibr">Ichinohe et&#x000a0;al., 2013</xref>).</p><p id="p0090">The pro-fission factor DRP1 is commonly targeted by viruses. Human immunodeficiency virus (HIV) via its protein gp120, for example, has been shown to reduce overall DRP1 and DRP1 phosphorylated at Ser616 levels and thus impair mitochondrial fission (<xref rid="bib32" ref-type="bibr">Fields et&#x000a0;al., 2016</xref>). Mitochondrial fission is believed to be important for clearance of defective mitochondria (<xref rid="bib88" ref-type="bibr">Pickles et&#x000a0;al., 2018</xref>). Therefore, it is tempting to speculate that prevention of the clearance of infected mitochondria by mitophagy supports viral replication and survival.</p><p id="p0095">Conversely, hepatitis B virus has been reported to induce mitochondrial fission by stimulating phosphorylation at Ser616. This facilitated mitophagy and enhanced viral survival by reducing virus-induced apoptosis (<xref rid="bib56" ref-type="bibr">Kim et&#x000a0;al., 2013</xref>). These examples demonstrate that viruses in principle can take advantage of both inhibition and enhancement of mitochondrial fission, in the described cases, primarily based on the modification of a single amino acid residue of DRP1, Ser616. The right balance of mitochondrial dynamics and mitophagy thus seems to be crucial in antiviral defense and in the regulation of inflammation (<xref rid="bib40" ref-type="bibr">Gkikas et&#x000a0;al., 2018</xref>).</p><p id="p0100">The RING-between-RING (RBR) E3 ubiquitin protein ligase parkin, which is involved in the induction of mitophagy, has recently emerged as another important mitochondria-associated modulator of innate immune function (<xref rid="bib70" ref-type="bibr">Manzanillo et&#x000a0;al., 2013</xref>). It has been shown that hepatitis B virus modulates parkin function for immune evasion by recruitment of the linear ubiquitin assembly complex (LUBAC) to mitochondria to disrupt MAVS downstream signaling (<xref rid="bib54" ref-type="bibr">Khan et&#x000a0;al., 2016</xref>).</p></sec><sec id="sec3.3"><title>NLRP3 and cGAS-STING</title><p id="p0105">Upon mitochondrial damage, mtDNA is released in the cytosol, where it can activate the NLRP3 inflammasome, a multi-protein complex that, mediated by caspase-1, promotes IL-1&#x003b2; and IL-18 secretion. NLRP3 is furthermore importantly regulated by mtROS and elevated mtROS activation of NLRP3 especially in bronchial epithelial cells may have detrimental consequences (<xref rid="bib57" ref-type="bibr">Kim et&#x000a0;al., 2014</xref>). Intriguingly, the loss of parkin has been recently associated with improved NLRP3-mediated viral clearance: parkin deficiency increased NLRP3 activation and anti-viral inflammation without affecting type I interferon production (<xref rid="bib65" ref-type="bibr">Li et&#x000a0;al., 2019</xref>).</p><p id="p0110">mtDNA released in the cytosol also gets detected by DNA-sensing enzymes, such as toll-like receptor 9 (TLR9) or GMP-AMP synthase (cGAS). cGAS detection of mtDNA in turn via stimulator of interferon genes (STING)-IRF3 promotes type I interferon responses, which increases resistance to viruses (<xref rid="bib122" ref-type="bibr">West et&#x000a0;al., 2015</xref>). Detection by cGAS activates cGAS-STING and interferon-based host responses. RNA viruses, including coronaviruses, have also evolved strategies to evade cGAS-STING (<xref rid="bib28" ref-type="bibr">Eaglesham and Kranzusch, 2020</xref>), comparable to the described MAVS evasion strategies. Strikingly, parkin also has been implicated in STING signaling, presumably regulating STING-induced inflammation (<xref rid="bib104" ref-type="bibr">Sliter et&#x000a0;al., 2018</xref>).</p><p id="p0115">In conclusion, mitochondria are involved in many pathways related to innate immune responses and viruses commonly undermine these mechanisms. In the next section we will assess the existing knowledge on the role of mitochondria in the innate immune system with regard to SARS-CoVs. We are not aware of published research on the direct role of parkin in SARS-CoV infection. But the central roles of mitochondrial dysfunction and of parkin, also in relation to inflammation (<xref rid="bib78" ref-type="bibr">Newman and Shadel, 2018</xref>), in sporadic and familial Parkinson disease, respectively, in combination with increasing evidence about COVID-19 as a potential risk factor for Parkinson disease (<xref rid="bib5" ref-type="bibr">Antonini et&#x000a0;al., 2020</xref>; <xref rid="bib84" ref-type="bibr">Papa et&#x000a0;al., 2020</xref>) are of great interest. Recent findings on the immediate relevance of influenza virus infection on Parkinson disease pathology (<xref rid="bib71" ref-type="bibr">Marreiros et&#x000a0;al., 2020</xref>) should additionally spur research on potential interdependencies of Parkinson disease and SARS-CoV-2 infection-related mechanisms.</p></sec></sec><sec id="sec4"><title>Manipulation of Mitochondrial Processes by SARS- Coronaviruses</title><p id="p0120">Many pathogens, including RNA viruses like CoVs, have developed targeted strategies to hijack mitochondria, damaging them or using them for their purposes, such as survival, propagation, or evading host immunity. Some viruses use mitochondrial membranes for genome replication (<xref rid="bib123" ref-type="bibr">West et&#x000a0;al., 2011</xref>). As shown for HIV infection, virus RNAs can also enter mitochondria, compromising mitochondrial integrity (<xref rid="bib106" ref-type="bibr">Somasundaran et&#x000a0;al., 1994</xref>). Recent computational work suggests that SARS-CoV-2 RNA preferentially localizes to mitochondria (<xref rid="bib124" ref-type="bibr">Wu et&#x000a0;al., 2020</xref>). Although no experimental data are yet available on whether this is really happening, SARS-CoV-2 RNA deposition in mitochondria could likewise impair mitochondrial function, potentially resulting in reduced energy and increased ROS generation (see part 5). Additional indirect support for a central role of mitochondria in SARS-CoV-2 infection comes from characteristic transcriptomic signatures of components of the oxidative phosphorylation system in peripheral mononuclear leukocytes and bronchoalveolar lavage fluid of patients with COVID-19 (<xref rid="bib36" ref-type="bibr">Gardinassi et&#x000a0;al., 2020</xref>).</p><sec id="sec4.1"><title>Host Evasion Mechanisms</title><p id="p0125">How SARS-CoV-2 evades the antiviral response is not well understood yet. But antagonistic mechanisms on cellular virus detection and interferon responses have been shown for SARS-CoV (<xref rid="bib115" ref-type="bibr">Totura and Baric, 2012</xref>) and MERS-CoV (<xref rid="bib100" ref-type="bibr">Shokri et&#x000a0;al., 2019</xref>) proteins. These mechanisms impede host responses to infection, e.g., by blunting interferon induction; support viral replication; and increase pyroptotic events, and may be active as well for SARS-CoV-2 (<xref rid="bib112" ref-type="bibr">Tay et&#x000a0;al., 2020</xref>). From animal studies on MERS-CoV infection, we know that blocking the interferon response has detrimental consequences on virus clearance and further immune responses (<xref rid="bib15" ref-type="bibr">Channappanavar et&#x000a0;al., 2019</xref>).</p><p id="p0130">A comprehensive overview on assumed host cell immunity evasion mechanisms of coronaviruses including SARS-CoV-2 has recently been published (<xref rid="bib117" ref-type="bibr">Vabret et&#x000a0;al., 2020</xref>). Some of these effects are afforded by the interaction of SARS-CoV proteins with cellular components affecting mitochondrial functions and thereby inhibiting immune responses. A systematically assembled list of such interactions for SARS-CoV is provided in <xref rid="tbl1" ref-type="table">Table 1</xref>
. Many of these interactions result in the suppression of interferon signaling or in the modulation of apoptosis. Some of the most interesting interactions with regard to the role of mitochondria in the innate immune system are briefly discussed below and depicted in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>
. All viral proteins mentioned in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>, except for ORF3b, are also expressed by SARS-CoV-2.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Interaction of SARS-CoV Proteins with Mitochondrial Innate Immunity Components</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Viral Component</th><th>Target</th><th>Reference</th></tr></thead><tbody><tr><td>Structural nucleocapsid protein</td><td><italic>Suppression of IRF responses, interference of RIG-1 activation</italic></td><td>(<xref rid="bib59" ref-type="bibr">Kopecky-Bromberg et&#x000a0;al., 2007</xref>), (<xref rid="bib47" ref-type="bibr">Hu et&#x000a0;al., 2017</xref>; <xref rid="bib68" ref-type="bibr">Lu et&#x000a0;al., 2011</xref>)</td></tr><tr><td>Structural membrane protein</td><td><italic>Suppression of RIG-1/MAVS</italic></td><td>(<xref rid="bib102" ref-type="bibr">Siu et&#x000a0;al., 2009</xref>)</td></tr><tr><td>S1 spike protein</td><td><italic>Induces apoptosis</italic></td><td>(<xref rid="bib19" ref-type="bibr">Chen et&#x000a0;al., 2018</xref>)</td></tr><tr><td>Envelop protein</td><td><italic>Activates NLRP3 inflammasome</italic></td><td>(<xref rid="bib80" ref-type="bibr">Nieto-Torres et&#x000a0;al., 2015</xref>)</td></tr><tr><td>Nsp1</td><td><italic>Suppression of IRF responses (downstream signaling)</italic></td><td>(<xref rid="bib51" ref-type="bibr">Jauregui et&#x000a0;al., 2013</xref>), (<xref rid="bib120" ref-type="bibr">Wathelet et&#x000a0;al., 2007</xref>)</td></tr><tr><td>Nsp2</td><td><italic>Inhibits PHB1 and 2 (blocking mitochondrial biogenesis)</italic></td><td>(<xref rid="bib22" ref-type="bibr">Cornillez-Ty et&#x000a0;al., 2009</xref>)</td></tr><tr><td>Nsp3</td><td><italic>Suppression of IRF responses (inhibits IRF3 phosphorylation)</italic></td><td>(<xref rid="bib75" ref-type="bibr">Mielech et&#x000a0;al., 2014</xref>)</td></tr><tr><td>Nsp15</td><td><italic>Inhibits MAVS-induced apoptosis</italic></td><td>(<xref rid="bib64" ref-type="bibr">Lei et&#x000a0;al., 2009</xref>)</td></tr><tr><td>ORF3a</td><td><italic>p38 MAP kinase &#x02192; modulates mitochondrial death pathways</italic></td><td>(<xref rid="bib82" ref-type="bibr">Padhan et&#x000a0;al., 2008</xref>)</td></tr><tr><td>ORF3a</td><td><italic>Activates NLRP3 inflammasome</italic></td><td>(<xref rid="bib17" ref-type="bibr">Chen et&#x000a0;al., 2019</xref>; <xref rid="bib103" ref-type="bibr">Siu et&#x000a0;al., 2019</xref>)</td></tr><tr><td>ORF3a</td><td><italic>Suppression of IRF responses (downstream signaling)</italic></td><td>(<xref rid="bib76" ref-type="bibr">Minakshi et&#x000a0;al., 2009</xref>)</td></tr><tr><td>ORF3b</td><td><italic>Suppression of IRF responses (inhibiting the phosphorylation and nuclear translocation of IRF3)</italic></td><td>(<xref rid="bib59" ref-type="bibr">Kopecky-Bromberg et&#x000a0;al., 2007</xref>)</td></tr><tr><td>ORF3b</td><td><italic>Inhibits RIG-1/MAVS</italic></td><td>(<xref rid="bib33" ref-type="bibr">Freundt et&#x000a0;al., 2009</xref>)</td></tr><tr><td>ORF6</td><td><italic>Suppression of IRF responses (downstream signaling)</italic></td><td>(<xref rid="bib59" ref-type="bibr">Kopecky-Bromberg et&#x000a0;al., 2007</xref>), (<xref rid="bib35" ref-type="bibr">Frieman et&#x000a0;al., 2007</xref>)</td></tr><tr><td>ORF7a</td><td><italic>Induces apoptosis</italic></td><td>(<xref rid="bib110" ref-type="bibr">Tan et&#x000a0;al., 2007</xref>)</td></tr><tr><td>ORF8a</td><td><italic>Increased mitochondrial membrane potential, ROS, and apoptosis</italic></td><td>(<xref rid="bib16" ref-type="bibr">Chen et&#x000a0;al., 2007</xref>)</td></tr><tr><td>ORF8b</td><td><italic>Activates NLRP3 inflammasome</italic></td><td>(<xref rid="bib98" ref-type="bibr">Shi et&#x000a0;al., 2019</xref>)</td></tr><tr><td>ORF9b</td><td><italic>Inhibits MAVS, induces degradation of DRP-1</italic></td><td>(<xref rid="bib97" ref-type="bibr">Shi et&#x000a0;al., 2014</xref>)</td></tr><tr><td>SARS-CoV PLpro</td><td><italic>Suppression of IRF responses (inhibits IRF3 phosphorylation)</italic></td><td>(<xref rid="bib26" ref-type="bibr">Devaraj et&#x000a0;al., 2007</xref>), (<xref rid="bib34" ref-type="bibr">Frieman et&#x000a0;al., 2009</xref>)</td></tr><tr><td>SARS-CoV PLpro</td><td><italic>Disruption of STING</italic></td><td>(<xref rid="bib108" ref-type="bibr">Sun et&#x000a0;al., 2012</xref>)</td></tr><tr><td>SARS-CoV 3C-like protease</td><td><italic>Overexpression changes expression of many mitochondrial proteins</italic></td><td>(<xref rid="bib63" ref-type="bibr">Lai et&#x000a0;al., 2007</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>Please see text for available information on SARS-CoV-2 proteins.</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Putative Mechanisms of Mitochondria-Related Immune Functions Manipulated by SARS-CoV and SARS-CoV-2</p><p>Red rectangles represent viral proteins, whose association with mitochondrial proteins of the host cells have been shown in SARS-CoV (except for Nsp4 and ORF9c, bold, for which interaction with mitochondrial components has been suggested only for SARS-CoV-2. ORF3b is not expressed in SARS-CoV-2). ETS, electron transport system.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0135">SARS-CoV nonstructural protein (Nsp) 2, for example, interacts with PHB1 and 2 and thereby impairs intracellular signaling and mitochondrial biogenesis (<xref rid="bib22" ref-type="bibr">Cornillez-Ty et&#x000a0;al., 2009</xref>; <xref rid="bib111" ref-type="bibr">Tatsuta and Langer, 2017</xref>) as well as MAVS (<xref rid="bib128" ref-type="bibr">Yoshinaka et&#x000a0;al., 2019</xref>). Open reading frame 3b (ORF3b) inhibits type I interferon induction and thus antiviral defense via interaction with the mitochondrial virus-detecting protein RIG-1 (<xref rid="bib33" ref-type="bibr">Freundt et&#x000a0;al., 2009</xref>). ORF8b of SARS-CoV has been shown to robustly activate the NLRP3 inflammasome (<xref rid="bib98" ref-type="bibr">Shi et&#x000a0;al., 2019</xref>). The SARS-CoV protein expressed from ORF9b localizes to mitochondria, promotes mitochondrial fusion and modulates the host antiviral defense (<xref rid="bib97" ref-type="bibr">Shi et&#x000a0;al., 2014</xref>). By increasing ubiquitination and proteasomal degradation of the mitochondrial fission factor DRP1, it favors mitochondrial fusion, possibly promoting cell survival during viral replication. ORF9b furthermore triggers the degradation of MAVS, severely limiting host cell interferon responses (<xref rid="bib97" ref-type="bibr">Shi et&#x000a0;al., 2014</xref>).</p><p id="p0140">Although experimental studies elucidating detailed mitochondrial modulation by SARS-CoV-2 are lacking, recent proteomic studies allow a preliminary assessment of the relevance of related findings in SARS-CoV. A recent SARS-CoV-2-human protein-protein interaction map derived from global affinity purification mass spectrometry analysis (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>) reveals putative interactions of SARS-CoV-2 proteins with human mitochondrial proteins, overlapping in many instances with available information on SARS-CoV. Beside a wide range of other human proteins, components of the innate immune system, including interferon signaling, were reported to possibly be regulated by viral proteins (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>). In line with the report on SARS-CoV ORF9b (<xref rid="bib97" ref-type="bibr">Shi et&#x000a0;al., 2014</xref>), <xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al. (2020)</xref> described potential modulation of MAVS by SARS-CoV-2 ORF9b via interaction with the mitochondrial import receptor TOM70. A very recent report also confirmed downregulation of MAVS in SARS-CoV-2-infected human colon epithelial carcinoma cells CaCo-2 (<xref rid="bib12" ref-type="bibr">Bojkova et&#x000a0;al., 2020</xref>).</p><p id="p0145">Gordon and colleagues' study (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>) furthermore indicates the interaction of several SARS-CoV-2 proteins with mitochondrial components that have not been reported yet for SARS-CoV: SARS-CoV-2 Nsp4 may interact with the mitochondrial import machinery (TIM complexes); Nsp8, with mitochondrial ribosomes, and ORF9c, with several components of the mitochondrial electron transport system. Nsp13 and Nsp15 furthermore may also interfere with interferon activation (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>). Experimental confirmation of these results is needed to assess the impact of SARS-CoV-2 proteins on mitochondrial functions.</p><p id="p0150">Manipulation of the cGAS-STING pathway by SARS-coronaviruses may also occur. SARS-CoV papain-like protease (PLpro), for example, which is also essential for CoV replication and spread, has been shown to interact with and inhibit STING (<xref rid="bib18" ref-type="bibr">Chen et&#x000a0;al., 2014</xref>; <xref rid="bib108" ref-type="bibr">Sun et&#x000a0;al., 2012</xref>). Similar to SARS-CoV PLpro, SARS-CoV-2 PLpro has recently been demonstrated to also impair type I interferon and NF-&#x003ba;B responses (<xref rid="bib99" ref-type="bibr">Shin et&#x000a0;al., 2020</xref>). Interestingly, SARS-CoV-2 PLpro exhibited a differential substrate specificity in this study, resulting in preferential cleavage of other host proteins than by SARS-CoV PLpro, highlighting mechanistic differences that may contribute to the different pathological outcomes of SARS and COVID-19.</p><p id="p0155">The innate immune response is furthermore targeted by SARS-CoV-2 by inhibition of translation. SARS-CoV-2 Nsp1, for example, has the potential to strongly impair translation of proteins involved in the anti-viral response, such as interferons and RIG-1, and the structural characterization of this process has recently been published (<xref rid="bib113" ref-type="bibr">Thoms et&#x000a0;al., 2020</xref>).</p><p id="p0160">Taken together, SARS-coronaviruses inhibit a number of mitochondrial antiviral defense mechanisms, including the reduction of interferon activation. It is known that pretreatment with interferon I/III is beneficial in SARS-CoV infection, but the protective effect may be even higher in SARS-CoV-2 (<xref rid="bib117" ref-type="bibr">Vabret et&#x000a0;al., 2020</xref>), suggesting similar or aggravated impairment of interferon activation in COVID-19.</p><p id="p0165">A summary of how SARS-CoV and SARS-CoV-2 modulate mitochondrial functions related to the innate immune system is depicted in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>.</p></sec><sec id="sec4.2"><title>Modulation of Mitochondria by SARS-CoV-2 and Oxygen Sensing</title><p id="p0170">SARS-CoV-2 infection may furthermore be related to reduced oxygen sensing mediated by mitochondrial dysfunction, as hypothesized by <xref rid="bib6" ref-type="bibr">Archer et&#x000a0;al. (2020)</xref>. It recently became apparent that ARDS related to SARS-CoV-2 infection when compared with traditional ARDS exhibits distinct manifestations: relatively preserved lung compliance, large intrapulmonary shunt, sometimes an absence of dyspnea (<xref rid="bib6" ref-type="bibr">Archer et&#x000a0;al., 2020</xref>; <xref rid="bib37" ref-type="bibr">Gattinoni et&#x000a0;al., 2020</xref>), pulmonary vessel abnormalities such as thrombosis, microangiopathy, and strongly increased angiogenesis (<xref rid="bib1" ref-type="bibr">Ackermann et&#x000a0;al., 2020</xref>). Mitochondrial oxidative stress may be directly involved in platelet dysfunction and coagulation pathways and contribute to elevated blood clotting and thrombosis (<xref rid="bib91" ref-type="bibr">Saleh et&#x000a0;al., 2020</xref>). Based on the observations of differential pathologies when compared with ARDS, Archer and colleagues speculated that hypoxemia in SARS-CoV-2 patients is caused by deficits in organismal oxygen sensing, which normally regulates oxygen uptake and systemic oxygen delivery. The response of the pulmonary circulation to pathological airway hypoxia is pulmonary artery constriction. This leads to changes in blood flow toward better ventilated alveoli. Reduced oxygen availability in the blood in turn is sensed by the carotid bodies, which induce increased respiration. <xref rid="bib6" ref-type="bibr">Archer et&#x000a0;al. (2020)</xref> argue that hypoxemia in patients infected with SARS-CoV-2 is most likely induced due to an impaired pulmonary artery constriction mechanism and carotid body dysfunction (see <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>
) that sometimes may be combined with infection-induced ARDS. These authors propose that oxygen-sensing mechanisms for pulmonary artery constriction and in the carotid bodies, which depend on the mitochondrial complex I subunit NDUFS2 (<xref rid="bib27" ref-type="bibr">Dunham-Snary et&#x000a0;al., 2019</xref>), are impaired following SARS-CoV-2 infection. Carotid bodies furthermore express ACE2 and thus maybe directly infected by SARS-CoV-2 (<xref rid="bib67" ref-type="bibr">Li and Schultz, 2006</xref>). Indeed, Gordon and colleagues identified several complex I subunits to interact with the SARS-CoV-2 proteins Nsp7 and ORF9c (although not NDUFS2), an interaction that the US Food and Drug Administration-approved diabetes drug metformin, which inhibits complex I and associated mtROS production and exerts a plethora of related and different molecular effects (<xref rid="bib62" ref-type="bibr">Kulkarni et&#x000a0;al., 2020</xref>), according to these authors' analysis could target (<xref rid="bib41" ref-type="bibr">Gordon et&#x000a0;al., 2020</xref>). Metformin's original purpose as an influenza drug (<xref rid="bib4" ref-type="bibr">Amin et&#x000a0;al., 2019</xref>) and other theoretical considerations, including regulation of ACE2 (<xref rid="bib95" ref-type="bibr">Sharma et&#x000a0;al., 2020</xref>), may suggest efficiency in COVID-19. Metformin furthermore reverses a typical inflammation phenotype of T&#x000a0;cells, observed both in aging and diabetes, by enhancing autophagy and mitochondrial bioenergetics (<xref rid="bib10" ref-type="bibr">Bharath et&#x000a0;al., 2020</xref>). Finally, the reduction of IL-6 release mediated by the inhibition of mitochondrial complex I-linked ROS production by metformin (<xref rid="bib105" ref-type="bibr">Soberanes et&#x000a0;al., 2019</xref>) has recently been directly linked to COVID-19 (<xref rid="bib73" ref-type="bibr">Menendez, 2020</xref>).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Possible Role of Mitochondrial Dysfunction in Aggravation of Hypoxemia in SARS-CoV-2</p><p>Mitochondrial dysfunction due to SARS-CoV2 infection contributes to pulmonary tissue damage, deterioration of pulmonary function, and airway hypoxia. Impaired mitochondria in the carotid bodies may worsen hypoxemia due to impaired oxygen sensing and result in a compromised chemoreflex. Oxidative stress and impaired anti-viral signaling lead to an imbalanced innate immune response.</p></caption><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0175">Taken together, modulation of mitochondria by viruses such as SARS-CoV-2 perturbs mitochondrial functions, possibly enabling host defense evasion strategies. SARS-CoV-2 induced oxygen-sensing deficiencies may aggravate systemic respirational deficits and promote severe infection outcome, but may be amenable to pharmacological treatments, necessitating intensified research.</p></sec></sec><sec id="sec5"><title>Mitochondrial Integrity and Antiviral Defense</title><p id="p0180">Mitochondrial dysfunction, for example, due to aging or chronic disease, negatively affects immunity and inflammation (<xref rid="bib72" ref-type="bibr">McGuire, 2019</xref>) and is a potential risk factor for SARS-CoV-2 infection. Mitochondrial integrity is paramount to mount adequate antiviral defense and prevent viral manipulation. Mitochondrial membrane potential, an important indicator of mitochondrial integrity, and oxidative phosphorylation have been shown to be necessary for the activation of the RLR-MAVS pathways (<xref rid="bib60" ref-type="bibr">Koshiba et&#x000a0;al., 2011</xref>; <xref rid="bib130" ref-type="bibr">Yoshizumi et&#x000a0;al., 2017</xref>). Moreover, the viral inhibition of MAVS by, e.g., the influenza virus protein PB1-F2 is achieved by a reduction of mitochondrial membrane potential (<xref rid="bib118" ref-type="bibr">Varga et&#x000a0;al., 2012</xref>; <xref rid="bib129" ref-type="bibr">Yoshizumi et&#x000a0;al., 2014</xref>). Supporting these results, diminished mitochondrial membrane potential is associated with a lower cytokine production after infection with various viruses (<xref rid="bib48" ref-type="bibr">Ichinohe et&#x000a0;al., 2013</xref>) and functional mitochondrial respiration is required to activate specialized immune cells (<xref rid="bib92" ref-type="bibr">Sander and Garaude, 2018</xref>).</p><p id="p0185">On the level of the lung, mitochondria not only provide energy for the regulation of airway and smooth muscles to regulate alveolar gas exchanges and to match ventilation and circulatory blood flow but also are integral for pulmonary cell and tissue protection (<xref rid="bib20" ref-type="bibr">Cloonan and Choi, 2016</xref>; <xref rid="bib87" ref-type="bibr">Piantadosi and Suliman, 2017</xref>). Acute lung injury is associated with mitochondrial dysfunction and oxidative stress (<xref rid="bib87" ref-type="bibr">Piantadosi and Suliman, 2017</xref>), thus it is reasonable that maintaining mitochondrial integrity will improve the outcome. Indeed, in a lipopolysaccharide-induced lung injury model the observed severe mitochondrial dysfunction of pulmonary epithelia could be readily prevented by mitochondrial transfer of functional mitochondria from bone marrow-derived stromal cells, resulting in reduced leukocytosis, protein leak, and mortality in mice (<xref rid="bib49" ref-type="bibr">Islam et&#x000a0;al., 2012</xref>).</p><p id="p0190">An overview of which mitochondrial functions related to the innate immune response are likely compromised by SARS-CoV-2 infection is depicted in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>
.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Perturbance of Energy Metabolism, Mitochondrial Dynamics, and Mitochondrial Anti-viral Signaling due to SARS-Coronavirus Infection</p><p>SARS-coronavirus infection is believed to induce mitochondrial dysfunction, resulting in oxidative phosphorylation (OXPHOS) deficits, the production of mtROS, dysregulated mitochondrial dynamics, and compromised mitochondrial anti-viral signaling. In combination with hypoxemia it may change cellular bioenergetics, favoring glycolysis over OXPHOS. In summary the new cellular conditions promote viral replication.</p></caption><graphic xlink:href="gr3_lrg"/></fig></p><p id="p0195">An interesting aspect about COVID-19 epidemiology is the modulatory effect of genetic sex on immune response and disease progression, with men being at higher risk. <xref rid="bib58" ref-type="bibr">Kloc et&#x000a0;al. (2020)</xref> recently summarized the potential involvement of sexually dimorphic populations of mitochondria in differential immune responses in general and in COVID-19 specifically. They argue that, beside other factors, sex hormone-dependent higher variation of female intestinal microbiomes may support the immune function in COVID-19 by providing more adequate substrates to mitochondria. Due to the maternal inheritance of mitochondria and the associated female-biased quality control, mitochondrial DNA mutations that are harmful for males but not females may furthermore persist during the mammalian egg maturation (<xref rid="bib58" ref-type="bibr">Kloc et&#x000a0;al., 2020</xref>). Although the relevance of these effects in COVID-19 is speculative at this stage, they support the potential involvement of mitochondrial dysfunction in COVID-19.</p><p id="p0200">How strongly mitochondrial integrity is involved in SARS-CoV-2 vulnerability remains to be tested experimentally. However, if compromised mitochondria are the reason for differential severity of COVID-19, this also warrants their assessment as biomarkers for disease progression as recently proposed (<xref rid="bib96" ref-type="bibr">Shenoy, 2020</xref>). Identification of patients with increased likelihood of severe COVID-19 (or future epidemics) outcome is essential to select appropriate treatments and manage potentially limited health care capacities. Coagulopathy, circulating pro-inflammatory stimuli, and low platelet counts emerge as integral aspects of COVID-19 and have been associated with the severity of the disease outcome (<xref rid="bib39" ref-type="bibr">Giannis et&#x000a0;al., 2020</xref>; <xref rid="bib74" ref-type="bibr">Merad and Martin, 2020</xref>). Oxidized phospholipids due to oxidative stress are linked to these pathologies, suggesting mitochondrial dysfunction or oxidative stress assessments to be candidates of peripherally measurable biomarkers. The recapitulation of mitochondrial dysfunction in blood samples of cardiac and skeletal muscles supports the investigation of the validity of such an approach for respiration (<xref rid="bib116" ref-type="bibr">Tyrrell et&#x000a0;al., 2016</xref>). Other blood-borne mitochondrial damage signals, like circulating dysfunctional, or functional (<xref rid="bib2" ref-type="bibr">Al Amir Dache et&#x000a0;al., 2020</xref>), mitochondria or mtDNA in peripheral blood cells may also hold promise (<xref rid="bib31" ref-type="bibr">Fetterman et&#x000a0;al., 2016</xref>). It has recently been argued that elevated oxidative and inflammatory states due to freely circulating mitochondria and mitochondrial components may result in dysfunction and apoptosis of platelets in COVID-19 and could thus be crucially involved in severe disease progression (<xref rid="bib91" ref-type="bibr">Saleh et&#x000a0;al., 2020</xref>).</p><p id="p0205">In this review we focused on mitochondrial involvement in the innate immune system of primarily affected cells in COVID-19: epithelial cells, alveolar epithelial cells, vascular endothelial cells, which constitute an important factor of lung-specific immune response (<xref rid="bib61" ref-type="bibr">Krausgruber et&#x000a0;al., 2020</xref>), and resident macrophages in the lung. Clearly, specialized immune cell function also strongly depends on metabolic factors (immunometabolism), and mitochondria and may be affected by SARS-CoV-2 infection as they are by SARS-CoV (<xref rid="bib114" ref-type="bibr">Tiku et&#x000a0;al., 2020</xref>). A very informative review on the effect of SARS-CoV-2 on different immune cell types has been provided by <xref rid="bib117" ref-type="bibr">Vabret et&#x000a0;al. (2020)</xref>; the knowledge on SARS-CoV-2-related immunometabolism is, however, still rudimentary. Activation of many immune cell types depends on mitochondrial function and oxidative phosphorylation (<xref rid="bib92" ref-type="bibr">Sander and Garaude, 2018</xref>), although upon activation they often primarily rely on glycolysis (<xref rid="bib8" ref-type="bibr">Banoth and Cassel, 2018</xref>). An excellent overview on these and related effects is provided in a recent review (<xref rid="bib69" ref-type="bibr">Makowski et&#x000a0;al., 2020</xref>). The exploration of the regulation and potential manipulation of mitochondria in specialized immune cells in SARS-CoV-2 will present another major scientific challenge.</p><p id="p0210">In summary, enhanced mitochondrial integrity may be beneficial in lung injury following respiratory infection and improved mitochondrial function may be protective for SARS-CoV-2 infection. An overview on valuable therapeutic possibilities, aside from metformin (see above), to improve conditions for the mitochondria-mediated innate immune response or generally enhance mitochondrial functions with regard to immunity is provided in <xref rid="tbox1" ref-type="boxed-text">Boxes 1</xref> and <xref rid="tbox2" ref-type="boxed-text">2</xref>
.<boxed-text id="tbox1"><label>Box 1</label><caption><title>Targeting Mitochondria to Enhance the Antiviral Immune Defense: Potential Applications for COVID-19</title></caption><p id="p0255">
<italic>a. Enhancing MAVS:</italic> Given its central role in the innate immune system, the major target MAVS seems to represent for SARS-CoVs, and the efficiency of interferon therapy in SARS-CoV infection, therapeutically targeting MAVS seems reasonable. <xref rid="bib107" ref-type="bibr">Song et&#x000a0;al. (2019)</xref> demonstrated the potential of D-glucosamine to upregulate MAVS efficiency by enhancing O-GlcNacylation of MAVS. This in turn promotes increased poly-ubiquitination of MAVS and thus induces more efficient induction of type I interferons via IRF3 signaling. The authors showed that a diet rich in D-glucosamine supplement indeed protected mice from RNA viruses such as human influenza virus.</p><p id="p0260">
<italic>b. Modulation of glycolysis in viral infection:</italic> Activation of the immune system induces changes in energy metabolism, mtROS production, and nutrient utilization and availability (<xref rid="bib92" ref-type="bibr">Sander and Garaude, 2018</xref>). Cells infected by RNA viruses often upregulate glycolysis and downregulate oxidative phosphorylation for energy production (<xref rid="bib50" ref-type="bibr">Ivashkiv, 2020</xref>), which might optimize viral replication conditions. The glycolysis product lactate inhibits RLR-mediated interferon activation, whereas glycolysis downregulation may be beneficial for the RLR-dependent anti-viral host defense (<xref rid="bib126" ref-type="bibr">Yasukawa et&#x000a0;al., 2020</xref>; <xref rid="bib133" ref-type="bibr">Zhang et&#x000a0;al., 2019</xref>). Activated specialized immune cells also rely more on glycolysis (<xref rid="bib92" ref-type="bibr">Sander and Garaude, 2018</xref>). Although a potential metabolic shift upon innate immune system activation toward glycolysis in SARS-CoV-2 infection is insufficiently explored, the attenuation of glycolysis by pharmacological tools, such as the glycolysis inhibitor 2-deoxy-D-glucose (2DG) (<xref rid="bib83" ref-type="bibr">P&#x000e5;lsson-McDermott and O'Neill, 2020</xref>), may represent a pharmacological avenue to explore.</p></boxed-text><boxed-text id="tbox2"><label>Box 2</label><caption><title>Boosting Mitochondria to Enhance the Innate Immunity: Potential Applications for COVID-19</title></caption><p id="p0265">
<italic>a. Boosting mitochondrial biogenesis and energy production:</italic> Mitochondria, most obviously and best studied in skeletal and cardiac muscles, respond rapidly to extracellular stimuli, such as exercise, by regulation of mitochondrial dynamics, mitochondrial membrane potential, and mitochondrial respiration (<xref rid="bib44" ref-type="bibr">Hood et&#x000a0;al., 2019</xref>). Moderate, regular exercise by ameliorating anti-oxidative capacities (<xref rid="bib13" ref-type="bibr">Bouzid et&#x000a0;al., 2018</xref>) is supposedly protective by preventing mitochondrial and tissue damage by exuberant ROS and can improve mitochondrial biogenesis, ATP production (<xref rid="bib29" ref-type="bibr">Egan and Zierath, 2013</xref>), and immunity (<xref rid="bib79" ref-type="bibr">Nieman and Wentz, 2019</xref>). Acute intensive bouts of exercise conversely reduce immune function transiently and thus are not to be recommended in the presence of infection risk (<xref rid="bib79" ref-type="bibr">Nieman and Wentz, 2019</xref>).</p><p id="p0270">One prominent example to boost mitochondrial function pharmacologically is the modulation of the nicotinamide dinucleotide (NAD+) synthesis (<xref rid="bib52" ref-type="bibr">Katsyuba et&#x000a0;al., 2020</xref>), the disruption of which has been demonstrated to be deleterious for the immune system (<xref rid="bib77" ref-type="bibr">Minhas et&#x000a0;al., 2019</xref>). Recently, <xref rid="bib42" ref-type="bibr">Heer et&#x000a0;al. (2020)</xref> indeed presented preliminary data that SARS-CoV-2 might dysregulate the NAD gene set, compromising immune responses.</p><p id="p0275">
<italic>b. Modulation of mitochondrial dynamics:</italic> SARS-coronaviruses are thought to modulate mitochondrial dynamics by degrading DRP1, thus favoring mitochondrial fusion. This may impair clearance of dysfunctional, for example, viral RNA or viral protein-containing, mitochondria and support survival of the infected cell during viral replication. Another consequence of impaired fission may be reduced cell membrane repair capacities of mitochondria for which fission is essential (<xref rid="bib45" ref-type="bibr">Horn et&#x000a0;al., 2020</xref>) and thereby could aggravate cell and tissue damage.</p><p id="p0280">Inhibition of fusion to restore homeostasis of fusion and fission thus may be beneficial for SARS-CoV-2 infection. Recently, a new pharmacological tool for this purpose was presented in the form of an OPA1 inhibitor. Notably, OPA1 in the study of <xref rid="bib43" ref-type="bibr">Herkenne et&#x000a0;al. (2020)</xref> also was shown to promote angiogenesis by limiting NF-&#x003ba;B. Angiogenesis is commonly controlled by viruses to establish microenvironments favorable for their own pathogenesis (<xref rid="bib3" ref-type="bibr">Alkharsah, 2018</xref>). OPA1 inhibition thus potentially has the capacity to also target another occasional pathological feature of SARS-CoV-2 infection, intussusceptive angiogenesis (<xref rid="bib1" ref-type="bibr">Ackermann et&#x000a0;al., 2020</xref>).</p><p id="p0285">On the other hand, mitochondrial fusion is thought to be generally beneficial for mitochondrial antiviral signaling, for example, by enhancing mitochondrial interaction with the endoplasmic reticulum by bringing MAVS and STING components closer together, and thus increasing the efficiency of type I interferon induction (<xref rid="bib85" ref-type="bibr">Pernas and Scorrano, 2016</xref>; <xref rid="bib123" ref-type="bibr">West et&#x000a0;al., 2011</xref>). Whether the benefits of fusion inhibition outweigh the expected negative effects on cellular anti-viral defense specifically by reduction of OPA1 (<xref rid="bib14" ref-type="bibr">Castanier et&#x000a0;al., 2010</xref>) and mitochondrial fusion in general remains to be investigated.</p></boxed-text></p></sec><sec id="sec6"><title>Future Perspectives</title><p id="p0215">Despite immense scientific efforts to further our understanding of SARS-CoV-2, the SARS-CoV-2 biology and COVID-19 pathogenesis are still poorly understood. Due to this reason, many of the here-presented interactions between mitochondria and SARS-CoV-2 remain speculative, with unclear clinical relevance warranting further research. Specifically, experimental evidences regarding the effects of SARS-CoV-2-induced mitochondrial dysfunctions in infected cells and in those affected secondarily by compromised oxygen supply are important. We hope with this perspective to motivate scientific investigation in the presented topics that in our opinion have great potential to better understand the biological basis of the ongoing pandemic and thus may contribute to improved management of COVID-19.</p><p id="p0220">In particular, the elucidation of the interactions between chronic diseases (both preconditions and as potential long-term effects of SARS-CoV-2) and COVID-19, specifically for metabolic and age-related diseases (e.g. Parkinson disease) is desirable. Epidemiological assessment of the correlation of chronic diseases involving mitochondrial dysfunctions is necessary to confirm the hypothesis that pre-existing mitochondrial deficits might predict infection and disease severity.</p><p id="p0225">Furthermore, if prominent mitochondrial dysfunction occurs in COVID-19, evaluation of its use as a biomarker for infection susceptibility and severity of disease progression will be of interest, thanks to accessible mitochondria-related biomarkers (e.g., in the blood), such as oxidative stress markers, respirational capacities of blood cells, or circulating mitochondrial DNA.</p><p id="p0230">Several strategies to target mitochondria, both pharmacologically and lifestyle interventions, hold promise to prevent SARS-CoV-2 infection or mitigate disease progression (see <xref rid="tbox1" ref-type="boxed-text">Box 1</xref>). Up to date, any experimental evidence on their potential is lacking. As mitochondria are often compromised following different types of viral infections, boosting their function might be an approach with potential not only in COVID-19 but also to fight other viruses. Targeting shared features of a broad array of viruses may be an important approach for future epidemics, especially as long as effective antibody treatments are lacking. Better understanding of mitochondrial involvement in immune functions eventually will also contribute to our understanding of the role of infections and inflammation in chronic diseases and aging.</p><p id="p0235">In conclusion, coronavirus infection may cause mitochondrial dysfunctions and functional mitochondria are integral for cell and tissue protection and for initiation and maintenance of immune responses. Here the manifold ways, how RNA viruses, and specifically SARS-coronaviruses, modulate mitochondrial function to evade the innate immune response of host cells, were summarized and put into context with the current understanding of SARS-CoV-2. We argue that enhancing or preserving mitochondrial function may prevent mitochondrial manipulation and dysfunction following viral infection. Regular physical activity or targeted pharmacological interventions to boost mitochondrial capacities are likely efficient to increase mitochondrial function and may enhance innate immunity in face of SARS-CoV-2 infection. In addition, the exploration of mitochondrial functions or mitochondrial damage markers in accessible tissues (e.g., blood) in response to SARS-CoV-2-infection may pave the way for the development of mitochondrial biomarkers for vulnerability and expected disease severity. The many knowledge gaps we currently have on SARS-CoV-2 biology and host pathophysiology give room for much future research.</p><p id="p0240">In summary, mitochondrial involvement in the innate immune response to SARS-CoV-2-infection represents a mechanism targetable by lifestyle and pharmacological strategies. Its thorough investigation is warranted for a better understanding of the pathogen-host biology and the development of adequate treatment strategies. Pre-existing mitochondrial dysfunction, for example, due to age or disease (e.g., cardiovascular disease, a prominent risk-factor of COVID-19), may represent factors contributing to differential vulnerabilities to SARS-CoV-2-infection and thus should be considered as a biomarker for the risk of infection and severity of outcome.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>M.</given-names></name><name><surname>Verleden</surname><given-names>S.E.</given-names></name><name><surname>Kuehnel</surname><given-names>M.</given-names></name><name><surname>Haverich</surname><given-names>A.</given-names></name><name><surname>Welte</surname><given-names>T.</given-names></name><name><surname>Laenger</surname><given-names>F.</given-names></name><name><surname>Vanstapel</surname><given-names>A.</given-names></name><name><surname>Werlein</surname><given-names>C.</given-names></name><name><surname>Stark</surname><given-names>H.</given-names></name><name><surname>Tzankov</surname><given-names>A.</given-names></name></person-group><article-title>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19</article-title><source>New Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">32437596</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Al Amir Dache</surname><given-names>Z.</given-names></name><name><surname>Otandault</surname><given-names>A.</given-names></name><name><surname>Tanos</surname><given-names>R.</given-names></name><name><surname>Pastor</surname><given-names>B.</given-names></name><name><surname>Meddeb</surname><given-names>R.</given-names></name><name><surname>Sanchez</surname><given-names>C.</given-names></name><name><surname>Arena</surname><given-names>G.</given-names></name><name><surname>Lasorsa</surname><given-names>L.</given-names></name><name><surname>Bennett</surname><given-names>A.</given-names></name><name><surname>Grange</surname><given-names>T.</given-names></name></person-group><article-title>Blood contains circulating cell-free respiratory competent mitochondria</article-title><source>FASEB J.</source><volume>34</volume><year>2020</year><fpage>3616</fpage><lpage>3630</lpage><pub-id pub-id-type="pmid">31957088</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Alkharsah</surname><given-names>K.R.</given-names></name></person-group><article-title>VEGF upregulation in viral infections and its possible therapeutic implications</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><year>2018</year><fpage>1642</fpage></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>S.</given-names></name><name><surname>Lux</surname><given-names>A.</given-names></name><name><surname>O'callaghan</surname><given-names>F.</given-names></name></person-group><article-title>The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth</article-title><source>Br. J. Clin. Pharmacol.</source><volume>85</volume><year>2019</year><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">30290005</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Antonini</surname><given-names>A.</given-names></name><name><surname>Leta</surname><given-names>V.</given-names></name><name><surname>Teo</surname><given-names>J.</given-names></name><name><surname>Chaudhuri</surname><given-names>K.R.</given-names></name></person-group><article-title>Outcome of Parkinson's Disease patients affected by COVID-19</article-title><source>Movement Disord.</source><volume>35</volume><year>2020</year><fpage>905</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">32347572</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>S.L.</given-names></name><name><surname>Sharp</surname><given-names>W.W.</given-names></name><name><surname>Weir</surname><given-names>E.K.</given-names></name></person-group><article-title>Differentiating COVID-19 Pneumonia from acute respiratory distress syndrome (ARDS) and high altitude pulmonary edema (HAPE): therapeutic implications</article-title><source>Circulation</source><volume>142</volume><year>2020</year><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">32369390</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Azkur</surname><given-names>A.K.</given-names></name><name><surname>Akdis</surname><given-names>M.</given-names></name><name><surname>Azkur</surname><given-names>D.</given-names></name><name><surname>Sokolowska</surname><given-names>M.</given-names></name><name><surname>van de Veen</surname><given-names>W.</given-names></name><name><surname>Bruggen</surname><given-names>M.C.</given-names></name><name><surname>O'Mahony</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Nadeau</surname><given-names>K.</given-names></name><name><surname>Akdis</surname><given-names>C.A.</given-names></name></person-group><article-title>Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19</article-title><source>Allergy</source><volume>75</volume><year>2020</year><fpage>1564</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">32396996</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Banoth</surname><given-names>B.</given-names></name><name><surname>Cassel</surname><given-names>S.L.</given-names></name></person-group><article-title>Mitochondria in innate immune signaling</article-title><source>Transl Res.</source><volume>202</volume><year>2018</year><fpage>52</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">30165038</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Belgnaoui</surname><given-names>S.M.</given-names></name><name><surname>Paz</surname><given-names>S.</given-names></name><name><surname>Hiscott</surname><given-names>J.</given-names></name></person-group><article-title>Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter</article-title><source>Curr. Opin. Immunol.</source><volume>23</volume><year>2011</year><fpage>564</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">21865020</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Bharath</surname><given-names>L.P.</given-names></name><name><surname>Agrawal</surname><given-names>M.</given-names></name><name><surname>McCambridge</surname><given-names>G.</given-names></name><name><surname>Nicholas</surname><given-names>D.A.</given-names></name><name><surname>Hasturk</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Deeney</surname><given-names>J.</given-names></name></person-group><article-title>Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation</article-title><source>Cell Metab.</source><volume>32</volume><year>2020</year><fpage>44</fpage><lpage>55.e6</lpage><pub-id pub-id-type="pmid">32402267</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name><surname>Liu</surname><given-names>W.-C.</given-names></name><name><surname>Uhl</surname><given-names>S.</given-names></name><name><surname>Hoagland</surname><given-names>D.</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>R.</given-names></name><name><surname>Jordan</surname><given-names>T.X.</given-names></name><name><surname>Oishi</surname><given-names>K.</given-names></name><name><surname>Panis</surname><given-names>M.</given-names></name><name><surname>Sachs</surname><given-names>D.</given-names></name></person-group><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>1036</fpage><lpage>1045.e9</lpage><pub-id pub-id-type="pmid">32416070</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Bojkova</surname><given-names>D.</given-names></name><name><surname>Klann</surname><given-names>K.</given-names></name><name><surname>Koch</surname><given-names>B.</given-names></name><name><surname>Widera</surname><given-names>M.</given-names></name><name><surname>Krause</surname><given-names>D.</given-names></name><name><surname>Ciesek</surname><given-names>S.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>M&#x000fc;nch</surname><given-names>C.</given-names></name></person-group><article-title>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets</article-title><source>Nature</source><volume>583</volume><year>2020</year><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">32408336</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Bouzid</surname><given-names>M.A.</given-names></name><name><surname>Filaire</surname><given-names>E.</given-names></name><name><surname>Matran</surname><given-names>R.</given-names></name><name><surname>Robin</surname><given-names>S.</given-names></name><name><surname>Fabre</surname><given-names>C.</given-names></name></person-group><article-title>Lifelong voluntary exercise modulates age-related changes in oxidative stress</article-title><source>Int. J. Sports Med.</source><volume>39</volume><year>2018</year><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">29169189</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Castanier</surname><given-names>C.</given-names></name><name><surname>Garcin</surname><given-names>D.</given-names></name><name><surname>Vazquez</surname><given-names>A.</given-names></name><name><surname>Arnoult</surname><given-names>D.</given-names></name></person-group><article-title>Mitochondrial dynamics regulate the RIG-I-like receptor antiviral pathway</article-title><source>EMBO Rep.</source><volume>11</volume><year>2010</year><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">20019757</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Abrahante</surname><given-names>J.E.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Sompallae</surname><given-names>R.</given-names></name><name><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</article-title><source>J.&#x000a0;Clin. Invest.</source><volume>130</volume><year>2019</year><fpage>3625</fpage><lpage>3639</lpage></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.Y.</given-names></name><name><surname>Ping</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Chen</surname><given-names>K.H.</given-names></name><name><surname>Lee</surname><given-names>Y.M.</given-names></name><name><surname>Chan</surname><given-names>Y.J.</given-names></name><name><surname>Lien</surname><given-names>T.C.</given-names></name><name><surname>Jap</surname><given-names>T.S.</given-names></name><name><surname>Lin</surname><given-names>C.H.</given-names></name><name><surname>Kao</surname><given-names>L.S.</given-names></name></person-group><article-title>Open reading frame 8a of the human severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis</article-title><source>J.&#x000a0;Infect Dis.</source><volume>196</volume><year>2007</year><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">17597455</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>I.Y.</given-names></name><name><surname>Moriyama</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>M.F.</given-names></name><name><surname>Ichinohe</surname><given-names>T.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome</article-title><source>Front. Microbiol.</source><volume>10</volume><year>2019</year><fpage>50</fpage><pub-id pub-id-type="pmid">30761102</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex</article-title><source>Protein &#x00026; Cell</source><volume>5</volume><year>2014</year><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">24622840</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Porcine epidemic diarrhea virus S1 protein is the critical inducer of apoptosis</article-title><source>Virol. J.</source><volume>15</volume><year>2018</year><fpage>170</fpage><pub-id pub-id-type="pmid">30404647</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Cloonan</surname><given-names>S.M.</given-names></name><name><surname>Choi</surname><given-names>A.M.</given-names></name></person-group><article-title>Mitochondria in lung disease</article-title><source>J.&#x000a0;Clin. Invest.</source><volume>126</volume><year>2016</year><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">26928034</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Cookson</surname><given-names>B.T.</given-names></name><name><surname>Brennan</surname><given-names>M.A.</given-names></name></person-group><article-title>Pro-inflammatory programmed cell death</article-title><source>Trends Microbiol.</source><volume>9</volume><year>2001</year><fpage>113</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11303500</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Cornillez-Ty</surname><given-names>C.T.</given-names></name><name><surname>Liao</surname><given-names>L.</given-names></name><name><surname>Yates</surname><given-names>J.R.</given-names></name><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling</article-title><source>J.&#x000a0;Virol.</source><volume>83</volume><year>2009</year><fpage>10314</fpage><lpage>10318</lpage><pub-id pub-id-type="pmid">19640993</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><collab>Coronaviridae Study Group, I</collab></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol.</source><volume>5</volume><year>2020</year><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Cribbs</surname><given-names>J.T.</given-names></name><name><surname>Strack</surname><given-names>S.</given-names></name></person-group><article-title>Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death</article-title><source>EMBO Rep.</source><volume>8</volume><year>2007</year><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">17721437</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Delgado-Roche</surname><given-names>L.</given-names></name><name><surname>Mesta</surname><given-names>F.</given-names></name></person-group><article-title>Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection</article-title><source>Arch. Med. Res.</source><volume>51</volume><year>2020</year><fpage>384</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">32402576</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S.G.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Tseng</surname><given-names>M.</given-names></name><name><surname>Barretto</surname><given-names>N.</given-names></name><name><surname>Lin</surname><given-names>R.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name><name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>282</volume><year>2007</year><fpage>32208</fpage><lpage>32221</lpage><pub-id pub-id-type="pmid">17761676</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Dunham-Snary</surname><given-names>K.J.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Potus</surname><given-names>F.</given-names></name><name><surname>Sykes</surname><given-names>E.A.</given-names></name><name><surname>Mewburn</surname><given-names>J.D.</given-names></name><name><surname>Charles</surname><given-names>R.L.</given-names></name><name><surname>Eaton</surname><given-names>P.</given-names></name><name><surname>Sultanian</surname><given-names>R.A.</given-names></name><name><surname>Archer</surname><given-names>S.L.</given-names></name></person-group><article-title>Ndufs2, a core subunit of mitochondrial complex I, is essential for acute oxygen-sensing and hypoxic pulmonary vasoconstriction</article-title><source>Circ. Res.</source><volume>124</volume><year>2019</year><fpage>1727</fpage><lpage>1746</lpage><pub-id pub-id-type="pmid">30922174</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Eaglesham</surname><given-names>J.B.</given-names></name><name><surname>Kranzusch</surname><given-names>P.J.</given-names></name></person-group><article-title>Conserved strategies for pathogen evasion of cGAS-STING immunity</article-title><source>Curr. Opin. Immunol.</source><volume>66</volume><year>2020</year><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">32339908</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>B.</given-names></name><name><surname>Zierath</surname><given-names>Juleen R.</given-names></name></person-group><article-title>Exercise metabolism and the molecular regulation of skeletal muscle adaptation</article-title><source>Cell Metab.</source><volume>17</volume><year>2013</year><fpage>162</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">23395166</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Fani</surname><given-names>M.</given-names></name><name><surname>Teimoori</surname><given-names>A.</given-names></name><name><surname>Ghafari</surname><given-names>S.</given-names></name></person-group><article-title>Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections</article-title><source>Future Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.2217/fvl-2020-0050</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Fetterman</surname><given-names>J.L.</given-names></name><name><surname>Holbrook</surname><given-names>M.</given-names></name><name><surname>Westbrook</surname><given-names>D.G.</given-names></name><name><surname>Brown</surname><given-names>J.A.</given-names></name><name><surname>Feeley</surname><given-names>K.P.</given-names></name><name><surname>Bret&#x000f3;n-Romero</surname><given-names>R.</given-names></name><name><surname>Linder</surname><given-names>E.A.</given-names></name><name><surname>Berk</surname><given-names>B.D.</given-names></name><name><surname>Weisbrod</surname><given-names>R.M.</given-names></name><name><surname>Widlansky</surname><given-names>M.E.</given-names></name></person-group><article-title>Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease</article-title><source>Cardiovasc. Diabetology</source><volume>15</volume><year>2016</year><fpage>53</fpage></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>J.A.</given-names></name><name><surname>Serger</surname><given-names>E.</given-names></name><name><surname>Campos</surname><given-names>S.</given-names></name><name><surname>Divakaruni</surname><given-names>A.S.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Trejo</surname><given-names>M.</given-names></name><name><surname>Adame</surname><given-names>A.</given-names></name><name><surname>Spencer</surname><given-names>B.</given-names></name><name><surname>Rockenstein</surname><given-names>E.</given-names></name></person-group><article-title>HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders</article-title><source>Neurobiol. Dis.</source><volume>86</volume><year>2016</year><fpage>154</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">26611103</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Freundt</surname><given-names>E.C.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Park</surname><given-names>E.</given-names></name><name><surname>Lenardo</surname><given-names>M.J.</given-names></name><name><surname>Xu</surname><given-names>X.-N.</given-names></name></person-group><article-title>Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein</article-title><source>J.&#x000a0;Virol.</source><volume>83</volume><year>2009</year><fpage>6631</fpage><lpage>6640</lpage><pub-id pub-id-type="pmid">19403678</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Johnston</surname><given-names>R.E.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling</article-title><source>J.&#x000a0;Virol.</source><volume>83</volume><year>2009</year><fpage>6689</fpage><lpage>6705</lpage><pub-id pub-id-type="pmid">19369340</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Heise</surname><given-names>M.</given-names></name><name><surname>Kopecky-Bromberg</surname><given-names>S.A.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>9812</fpage><lpage>9824</lpage><pub-id pub-id-type="pmid">17596301</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Gardinassi</surname><given-names>L.G.</given-names></name><name><surname>Souza</surname><given-names>C.O.S.</given-names></name><name><surname>Sales-Campos</surname><given-names>H.</given-names></name><name><surname>Fonseca</surname><given-names>S.G.</given-names></name></person-group><article-title>Immune and metabolic signatures of COVID-19 revealed by transcriptomics data reuse</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>1636</fpage><pub-id pub-id-type="pmid">32670298</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L.</given-names></name><name><surname>Coppola</surname><given-names>S.</given-names></name><name><surname>Cressoni</surname><given-names>M.</given-names></name><name><surname>Busana</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>S.</given-names></name><name><surname>Chiumello</surname><given-names>D.</given-names></name></person-group><article-title>COVID-19 does not lead to a "typical" acute respiratory distress syndrome</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>201</volume><year>2020</year><fpage>1299</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">32228035</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Giacomello</surname><given-names>M.</given-names></name><name><surname>Pyakurel</surname><given-names>A.</given-names></name><name><surname>Glytsou</surname><given-names>C.</given-names></name><name><surname>Scorrano</surname><given-names>L.</given-names></name></person-group><article-title>The cell biology of mitochondrial membrane dynamics</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>21</volume><year>2020</year><fpage>204</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">32071438</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Giannis</surname><given-names>D.</given-names></name><name><surname>Ziogas</surname><given-names>I.A.</given-names></name><name><surname>Gianni</surname><given-names>P.</given-names></name></person-group><article-title>Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past</article-title><source>J.&#x000a0;Clin. Virol.</source><volume>127</volume><year>2020</year><fpage>104362</fpage><pub-id pub-id-type="pmid">32305883</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Gkikas</surname><given-names>I.</given-names></name><name><surname>Palikaras</surname><given-names>K.</given-names></name><name><surname>Tavernarakis</surname><given-names>N.</given-names></name></person-group><article-title>The role of mitophagy in innate immunity</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1283</fpage><pub-id pub-id-type="pmid">29951054</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>D.E.</given-names></name><name><surname>Jang</surname><given-names>G.M.</given-names></name><name><surname>Bouhaddou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Obernier</surname><given-names>K.</given-names></name><name><surname>White</surname><given-names>K.M.</given-names></name><name><surname>O&#x02019;Meara</surname><given-names>M.J.</given-names></name><name><surname>Rezelj</surname><given-names>V.V.</given-names></name><name><surname>Guo</surname><given-names>J.Z.</given-names></name><name><surname>Swaney</surname><given-names>D.L.</given-names></name></person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title><source>Nature</source><volume>583</volume><year>2020</year><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">32353859</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Heer</surname><given-names>C.D.</given-names></name><name><surname>Sanderson</surname><given-names>D.J.</given-names></name><name><surname>Alhammad</surname><given-names>Y.M.O.</given-names></name><name><surname>Schmidt</surname><given-names>M.S.</given-names></name><name><surname>Trammell</surname><given-names>S.A.J.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>M.S.</given-names></name><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Brenner</surname><given-names>C.</given-names></name></person-group><article-title>Coronavirus infection and PARP expression dysregulate the NAD metabolome: a potentially actionable component of innate immunity</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.17.047480</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Herkenne</surname><given-names>S.</given-names></name><name><surname>Ek</surname><given-names>O.</given-names></name><name><surname>Zamberlan</surname><given-names>M.</given-names></name><name><surname>Pellattiero</surname><given-names>A.</given-names></name><name><surname>Chergova</surname><given-names>M.</given-names></name><name><surname>Chivite</surname><given-names>I.</given-names></name><name><surname>Novotn&#x000e1;</surname><given-names>E.</given-names></name><name><surname>Rigoni</surname><given-names>G.</given-names></name><name><surname>Fonseca</surname><given-names>T.B.</given-names></name><name><surname>Samardzic</surname><given-names>D.</given-names></name></person-group><article-title>Developmental and tumor angiogenesis requires the mitochondria-shaping protein Opa1</article-title><source>Cell Metab.</source><volume>31</volume><year>2020</year><fpage>987</fpage><lpage>1003.e8</lpage><pub-id pub-id-type="pmid">32315597</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Hood</surname><given-names>D.A.</given-names></name><name><surname>Memme</surname><given-names>J.M.</given-names></name><name><surname>Oliveira</surname><given-names>A.N.</given-names></name><name><surname>Triolo</surname><given-names>M.</given-names></name></person-group><article-title>Maintenance of skeletal muscle mitochondria in health, exercise, and aging</article-title><source>Annu. Rev. Physiol.</source><volume>81</volume><year>2019</year><fpage>19</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">30216742</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>A.</given-names></name><name><surname>Raavicharla</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Cox</surname><given-names>D.</given-names></name><name><surname>Jaiswal</surname><given-names>J.K.</given-names></name></person-group><article-title>Mitochondrial fragmentation enables localized signaling required for cell repair</article-title><source>J.&#x000a0;Cell Biol.</source><volume>219</volume><year>2020</year><fpage>e201909154</fpage><pub-id pub-id-type="pmid">32236517</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Skaug</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>Q.-X.</given-names></name><name><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response</article-title><source>Cell</source><volume>146</volume><year>2011</year><fpage>448</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">21782231</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name></person-group><article-title>The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination</article-title><source>J.&#x000a0;Virol.</source><volume>91</volume><year>2017</year><comment>e02143&#x02013;02116</comment></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T.</given-names></name><name><surname>Yamazaki</surname><given-names>T.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name><name><surname>Yanagi</surname><given-names>Y.</given-names></name></person-group><article-title>Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection</article-title><source>Proc. Natl. Acad. Sci.</source><volume>110</volume><year>2013</year><fpage>17963</fpage><lpage>17968</lpage><pub-id pub-id-type="pmid">24127597</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>M.N.</given-names></name><name><surname>Das</surname><given-names>S.R.</given-names></name><name><surname>Emin</surname><given-names>M.T.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Westphalen</surname><given-names>K.</given-names></name><name><surname>Rowlands</surname><given-names>D.J.</given-names></name><name><surname>Quadri</surname><given-names>S.K.</given-names></name><name><surname>Bhattacharya</surname><given-names>S.</given-names></name><name><surname>Bhattacharya</surname><given-names>J.</given-names></name></person-group><article-title>Mitochondrial transfer from bone-marrow&#x02013;derived stromal cells to pulmonary alveoli protects against acute lung injury</article-title><source>Nat. Med.</source><volume>18</volume><year>2012</year><fpage>759</fpage><pub-id pub-id-type="pmid">22504485</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>L.B.</given-names></name></person-group><article-title>The hypoxia&#x02013;lactate axis tempers inflammation</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>85</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">31819164</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Jauregui</surname><given-names>A.R.</given-names></name><name><surname>Savalia</surname><given-names>D.</given-names></name><name><surname>Lowry</surname><given-names>V.K.</given-names></name><name><surname>Farrell</surname><given-names>C.M.</given-names></name><name><surname>Wathelet</surname><given-names>M.G.</given-names></name></person-group><article-title>Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e62416</fpage><pub-id pub-id-type="pmid">23658627</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Katsyuba</surname><given-names>E.</given-names></name><name><surname>Romani</surname><given-names>M.</given-names></name><name><surname>Hofer</surname><given-names>D.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name></person-group><article-title>NAD+ homeostasis in health and disease</article-title><source>Nat. Metab.</source><volume>2</volume><year>2020</year><fpage>9</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">32694684</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Syed</surname><given-names>G.H.</given-names></name><name><surname>Kim</surname><given-names>S.-J.</given-names></name><name><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial dynamics and viral infections: a close nexus</article-title><source>Biochim. Biophys. Acta (Bba) - Mol. Cell Res.</source><volume>1853</volume><year>2015</year><fpage>2822</fpage><lpage>2833</lpage></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Syed</surname><given-names>G.H.</given-names></name><name><surname>Kim</surname><given-names>S.-J.</given-names></name><name><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group><article-title>Hepatitis B virus-induced parkin-dependent recruitment of linear ubiquitin assembly complex (LUBAC) to mitochondria and attenuation of innate immunity</article-title><source>PLoS Pathog.</source><volume>12</volume><year>2016</year><fpage>e1005693</fpage><pub-id pub-id-type="pmid">27348524</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.-J.</given-names></name><name><surname>Ahn</surname><given-names>D.-G.</given-names></name><name><surname>Syed</surname><given-names>G.H.</given-names></name><name><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group><article-title>The essential role of mitochondrial dynamics in antiviral immunity</article-title><source>Mitochondrion</source><volume>41</volume><year>2018</year><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">29246869</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Quan</surname><given-names>J.</given-names></name><name><surname>Till</surname><given-names>A.</given-names></name><name><surname>Subramani</surname><given-names>S.</given-names></name><name><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group><article-title>Hepatitis B virus disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis</article-title><source>Plos Pathog.</source><volume>9</volume><year>2013</year><fpage>e1003722</fpage><pub-id pub-id-type="pmid">24339771</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.R.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name><name><surname>Cho</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>Y.C.</given-names></name></person-group><article-title>NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation</article-title><source>Cell Death Dis.</source><volume>5</volume><year>2014</year><fpage>e1498</fpage><pub-id pub-id-type="pmid">25356867</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Kloc</surname><given-names>M.</given-names></name><name><surname>Ghobrial</surname><given-names>R.M.</given-names></name><name><surname>Kubiak</surname><given-names>J.Z.</given-names></name></person-group><article-title>The role of genetic sex and mitochondria in response to COVID-19 infection</article-title><source>Int. Arch. Allergy Immunol.</source><volume>181</volume><year>2020</year><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">32564017</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Kopecky-Bromberg</surname><given-names>S.A.</given-names></name><name><surname>Mart&#x000ed;nez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Baric</surname><given-names>R.A.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>548</fpage><pub-id pub-id-type="pmid">17108024</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Koshiba</surname><given-names>T.</given-names></name><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Yanagi</surname><given-names>Y.</given-names></name><name><surname>Kawabata</surname><given-names>S.-i.</given-names></name></person-group><article-title>Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling</article-title><source>Sci. Signal.</source><volume>4</volume><year>2011</year><fpage>ra7</fpage><pub-id pub-id-type="pmid">21285412</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Krausgruber</surname><given-names>T.</given-names></name><name><surname>Fortelny</surname><given-names>N.</given-names></name><name><surname>Fife-Gernedl</surname><given-names>V.</given-names></name><name><surname>Senekowitsch</surname><given-names>M.</given-names></name><name><surname>Schuster</surname><given-names>L.C.</given-names></name><name><surname>Lercher</surname><given-names>A.</given-names></name><name><surname>Nemc</surname><given-names>A.</given-names></name><name><surname>Schmidl</surname><given-names>C.</given-names></name><name><surname>Rendeiro</surname><given-names>A.F.</given-names></name><name><surname>Bergthaler</surname><given-names>A.</given-names></name></person-group><article-title>Structural cells are key regulators of organ-specific immune responses</article-title><source>Nature</source><volume>583</volume><year>2020</year><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">32612232</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>A.S.</given-names></name><name><surname>Gubbi</surname><given-names>S.</given-names></name><name><surname>Barzilai</surname><given-names>N.</given-names></name></person-group><article-title>Benefits of metformin in attenuating the hallmarks of aging</article-title><source>Cell Metab.</source><volume>32</volume><year>2020</year><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">32333835</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.C.</given-names></name><name><surname>Jou</surname><given-names>M.J.</given-names></name><name><surname>Huang</surname><given-names>S.Y.</given-names></name><name><surname>Li</surname><given-names>S.W.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Tsai</surname><given-names>F.J.</given-names></name><name><surname>Lin</surname><given-names>C.W.</given-names></name></person-group><article-title>Proteomic analysis of up-regulated proteins in human promonocyte cells expressing severe acute respiratory syndrome coronavirus 3C-like protease</article-title><source>Proteomics</source><volume>7</volume><year>2007</year><fpage>1446</fpage><lpage>1460</lpage><pub-id pub-id-type="pmid">17407183</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y.</given-names></name><name><surname>Moore</surname><given-names>C.B.</given-names></name><name><surname>Liesman</surname><given-names>R.M.</given-names></name><name><surname>O'Connor</surname><given-names>B.P.</given-names></name><name><surname>Bergstralh</surname><given-names>D.T.</given-names></name><name><surname>Chen</surname><given-names>Z.J.</given-names></name><name><surname>Pickles</surname><given-names>R.J.</given-names></name><name><surname>Ting</surname><given-names>J.P.</given-names></name></person-group><article-title>MAVS-mediated apoptosis and its inhibition by viral proteins</article-title><source>PLoS One</source><volume>4</volume><year>2009</year><fpage>e5466</fpage><pub-id pub-id-type="pmid">19404494</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Long</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Parkin impairs antiviral immunity by suppressing the mitochondrial reactive oxygen species-Nlrp3 axis and antiviral inflammation</article-title><source>iScience</source><volume>16</volume><year>2019</year><fpage>468</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">31229895</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.-D.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Seth</surname><given-names>R.B.</given-names></name><name><surname>Pineda</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity</article-title><source>Proc. Natl. Acad. Sci.</source><volume>102</volume><year>2005</year><fpage>17717</fpage><lpage>17722</lpage><pub-id pub-id-type="pmid">16301520</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.L.</given-names></name><name><surname>Schultz</surname><given-names>H.D.</given-names></name></person-group><article-title>Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II</article-title><source>J.&#x000a0;Physiol.</source><volume>575</volume><year>2006</year><fpage>215</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16777942</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>J.a.</given-names></name><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>SARS-CoV nucleocapsid protein antagonizes IFN-&#x003b2; response by targeting initial step of IFN-&#x003b2; induction pathway, and its C-terminal region is critical for the antagonism</article-title><source>Virus genes</source><volume>42</volume><year>2011</year><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">20976535</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Makowski</surname><given-names>L.</given-names></name><name><surname>Chaib</surname><given-names>M.</given-names></name><name><surname>Rathmell</surname><given-names>J.C.</given-names></name></person-group><article-title>Immunometabolism: from basic mechanisms to translation</article-title><source>Immunological Rev.</source><volume>295</volume><year>2020</year><fpage>5</fpage><lpage>14</lpage></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Manzanillo</surname><given-names>P.S.</given-names></name><name><surname>Ayres</surname><given-names>J.S.</given-names></name><name><surname>Watson</surname><given-names>R.O.</given-names></name><name><surname>Collins</surname><given-names>A.C.</given-names></name><name><surname>Souza</surname><given-names>G.</given-names></name><name><surname>Rae</surname><given-names>C.S.</given-names></name><name><surname>Schneider</surname><given-names>D.S.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Shiloh</surname><given-names>M.U.</given-names></name><name><surname>Cox</surname><given-names>J.S.</given-names></name></person-group><article-title>The ubiquitin ligase parkin mediates resistance to intracellular pathogens</article-title><source>Nature</source><volume>501</volume><year>2013</year><fpage>512</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">24005326</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Marreiros</surname><given-names>R.</given-names></name><name><surname>M&#x000fc;ller-Schiffmann</surname><given-names>A.</given-names></name><name><surname>Trossbach</surname><given-names>S.V.</given-names></name><name><surname>Prikulis</surname><given-names>I.</given-names></name><name><surname>H&#x000e4;nsch</surname><given-names>S.</given-names></name><name><surname>Weidtkamp-Peters</surname><given-names>S.</given-names></name><name><surname>Moreira</surname><given-names>A.R.</given-names></name><name><surname>Sahu</surname><given-names>S.</given-names></name><name><surname>Soloviev</surname><given-names>I.</given-names></name><name><surname>Selvarajah</surname><given-names>S.</given-names></name></person-group><article-title>Disruption of cellular proteostasis by H1N1 influenza A virus causes &#x003b1;-synuclein aggregation</article-title><source>Proc. Natl. Acad. Sci.</source><volume>117</volume><year>2020</year><fpage>6741</fpage><lpage>6751</lpage><pub-id pub-id-type="pmid">32152117</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>P.J.</given-names></name></person-group><article-title>Mitochondrial dysfunction and the aging immune system</article-title><source>Biology</source><volume>8</volume><year>2019</year><fpage>26</fpage></element-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>J.</given-names></name></person-group><article-title>Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19</article-title><source>Aging</source><volume>12</volume><year>2020</year><fpage>8760</fpage><lpage>8765</lpage><pub-id pub-id-type="pmid">32463794</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>J.C.</given-names></name></person-group><article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">32376901</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Mielech</surname><given-names>A.M.</given-names></name><name><surname>Kilianski</surname><given-names>A.</given-names></name><name><surname>Baez-Santos</surname><given-names>Y.M.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>MERS-CoV papain-like protease has deISGylating and deubiquitinating activities</article-title><source>Virology</source><volume>450-451</volume><year>2014</year><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">24503068</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Minakshi</surname><given-names>R.</given-names></name><name><surname>Padhan</surname><given-names>K.</given-names></name><name><surname>Rani</surname><given-names>M.</given-names></name><name><surname>Khan</surname><given-names>N.</given-names></name><name><surname>Ahmad</surname><given-names>F.</given-names></name><name><surname>Jameel</surname><given-names>S.</given-names></name></person-group><article-title>The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor</article-title><source>PLoS One</source><volume>4</volume><year>2009</year><fpage>e8342</fpage><pub-id pub-id-type="pmid">20020050</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>P.S.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Moon</surname><given-names>P.K.</given-names></name><name><surname>Joshi</surname><given-names>A.U.</given-names></name><name><surname>Dove</surname><given-names>C.</given-names></name><name><surname>Mhatre</surname><given-names>S.</given-names></name><name><surname>Contrepois</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Lee</surname><given-names>B.A.</given-names></name><name><surname>Coronado</surname><given-names>M.</given-names></name></person-group><article-title>Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation</article-title><source>Nat. Immunol.</source><volume>20</volume><year>2019</year><fpage>50</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">30478397</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>L.E.</given-names></name><name><surname>Shadel</surname><given-names>G.S.</given-names></name></person-group><article-title>Pink1/Parkin link inflammation, mitochondrial stress, and neurodegeneration</article-title><source>J.&#x000a0;Cell. Biol.</source><volume>217</volume><year>2018</year><fpage>3327</fpage><lpage>3329</lpage><pub-id pub-id-type="pmid">30154188</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Nieman</surname><given-names>D.C.</given-names></name><name><surname>Wentz</surname><given-names>L.M.</given-names></name></person-group><article-title>The compelling link between physical activity and the body's defense system</article-title><source>J.&#x000a0;Sport Health Sci.</source><volume>8</volume><year>2019</year><fpage>201</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">31193280</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name><name><surname>Verdi&#x000e1;-B&#x000e1;guena</surname><given-names>C.</given-names></name><name><surname>Jimenez-Guarde&#x000f1;o</surname><given-names>J.M.</given-names></name><name><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name><surname>Casta&#x000f1;o-Rodriguez</surname><given-names>C.</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name><surname>Torres</surname><given-names>J.</given-names></name><name><surname>Aguilella</surname><given-names>V.M.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome</article-title><source>Virology</source><volume>485</volume><year>2015</year><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">26331680</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Onoguchi</surname><given-names>K.</given-names></name><name><surname>Onomoto</surname><given-names>K.</given-names></name><name><surname>Takamatsu</surname><given-names>S.</given-names></name><name><surname>Jogi</surname><given-names>M.</given-names></name><name><surname>Takemura</surname><given-names>A.</given-names></name><name><surname>Morimoto</surname><given-names>S.</given-names></name><name><surname>Julkunen</surname><given-names>I.</given-names></name><name><surname>Namiki</surname><given-names>H.</given-names></name><name><surname>Yoneyama</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>T.</given-names></name></person-group><article-title>Virus-infection or 5&#x02032; ppp-RNA activates antiviral signal through redistribution of IPS-1 mediated by MFN1</article-title><source>PLoS Pathog.</source><volume>6</volume><year>2010</year><fpage>e1001012</fpage><pub-id pub-id-type="pmid">20661427</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Padhan</surname><given-names>K.</given-names></name><name><surname>Minakshi</surname><given-names>R.</given-names></name><name><surname>Towheed</surname><given-names>M.A.B.</given-names></name><name><surname>Jameel</surname><given-names>S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus 3a protein activates the mitochondrial death pathway through p38 MAP kinase activation</article-title><source>J.&#x000a0;Gen. Virol.</source><volume>89</volume><year>2008</year><fpage>1960</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">18632968</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>P&#x000e5;lsson-McDermott</surname><given-names>E.M.</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>L.A.J.</given-names></name></person-group><article-title>Targeting immunometabolism as an anti-inflammatory strategy</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>300</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">32132672</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>S.M.</given-names></name><name><surname>Brundin</surname><given-names>P.</given-names></name><name><surname>Fung</surname><given-names>V.S.</given-names></name><name><surname>Kang</surname><given-names>U.J.</given-names></name><name><surname>Burn</surname><given-names>D.J.</given-names></name><name><surname>Colosimo</surname><given-names>C.</given-names></name><name><surname>Chiang</surname><given-names>H.L.</given-names></name><name><surname>Alcalay</surname><given-names>R.N.</given-names></name><name><surname>Trenkwalder</surname><given-names>C.</given-names></name><name><surname>Committee</surname><given-names>M.-S.I.</given-names></name></person-group><article-title>Impact of the COVID-19 pandemic on Parkinson&#x02019;s disease and movement disorders</article-title><source>Mov. Disord.</source><volume>35</volume><year>2020</year><fpage>711</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">32250460</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Pernas</surname><given-names>L.</given-names></name><name><surname>Scorrano</surname><given-names>L.</given-names></name></person-group><article-title>Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function</article-title><source>Annu. Rev. Physiol.</source><volume>78</volume><year>2016</year><fpage>505</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">26667075</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>E.</given-names></name><name><surname>Koopmans</surname><given-names>M.</given-names></name><name><surname>Go</surname><given-names>U.</given-names></name><name><surname>Hamer</surname><given-names>D.H.</given-names></name><name><surname>Petrosillo</surname><given-names>N.</given-names></name><name><surname>Castelli</surname><given-names>F.</given-names></name><name><surname>Storgaard</surname><given-names>M.</given-names></name><name><surname>Al Khalili</surname><given-names>S.</given-names></name><name><surname>Simonsen</surname><given-names>L.</given-names></name></person-group><article-title>Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>e238</fpage><lpage>e244</lpage><pub-id pub-id-type="pmid">32628905</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Piantadosi</surname><given-names>C.A.</given-names></name><name><surname>Suliman</surname><given-names>H.B.</given-names></name></person-group><article-title>Mitochondrial dysfunction in lung pathogenesis</article-title><source>Annu. Rev. Physiol.</source><volume>79</volume><year>2017</year><fpage>495</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">27959621</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Pickles</surname><given-names>S.</given-names></name><name><surname>Vigi&#x000e9;</surname><given-names>P.</given-names></name><name><surname>Youle</surname><given-names>R.J.</given-names></name></person-group><article-title>Mitophagy and quality control mechanisms in mitochondrial maintenance</article-title><source>Curr. Biol.</source><volume>28</volume><year>2018</year><fpage>R170</fpage><lpage>R185</lpage><pub-id pub-id-type="pmid">29462587</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Rockx</surname><given-names>B.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name><name><surname>Herfst</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.</given-names></name><name><surname>Lamers</surname><given-names>M.M.</given-names></name><name><surname>Oude Munnink</surname><given-names>B.B.</given-names></name><name><surname>de Meulder</surname><given-names>D.</given-names></name><name><surname>van Amerongen</surname><given-names>G.</given-names></name><name><surname>van den Brand</surname><given-names>J.</given-names></name><name><surname>Okba</surname><given-names>N.M.A.</given-names></name></person-group><article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>1012</fpage><pub-id pub-id-type="pmid">32303590</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title><source>Intensive Care Med.</source><volume>46</volume><year>2020</year><fpage>846</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">32125452</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>J.</given-names></name><name><surname>Peyssonnaux</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>K.K.</given-names></name><name><surname>Edeas</surname><given-names>M.</given-names></name></person-group><article-title>Mitochondria and microbiota dysfunction in COVID-19 pathogenesis</article-title><source>Mitochondrion</source><volume>54</volume><year>2020</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">32574708</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>L.E.</given-names></name><name><surname>Garaude</surname><given-names>J.</given-names></name></person-group><article-title>The mitochondrial respiratory chain: a metabolic rheostat of innate immune cell-mediated antibacterial responses</article-title><source>Mitochondrion</source><volume>41</volume><year>2018</year><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">29054472</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>O.</given-names></name><name><surname>Yoshizumi</surname><given-names>T.</given-names></name><name><surname>Kuboyama</surname><given-names>M.</given-names></name><name><surname>Ishihara</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>E.</given-names></name><name><surname>Kawabata</surname><given-names>S.-i.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>A structural perspective of the MAVS-regulatory mechanism on the mitochondrial outer membrane using bioluminescence resonance energy transfer</article-title><source>Biochim. Biophys. Acta (Bba) - Mol. Cell Res.</source><volume>1833</volume><year>2013</year><fpage>1017</fpage><lpage>1027</lpage></element-citation></ref><ref id="bib94"><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Schrepfer</surname><given-names>E.</given-names></name><name><surname>Scorrano</surname><given-names>L.</given-names></name></person-group><article-title>Mitofusins, from mitochondria to metabolism</article-title><source>Mol. Cell</source><volume>61</volume><year>2016</year><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">26942673</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>A.</given-names></name><name><surname>Sadasivam</surname><given-names>B.</given-names></name></person-group><article-title>Metformin in COVID-19: a possible role beyond diabetes</article-title><source>Diabetes Res. Clin. Pract.</source><volume>164</volume><year>2020</year><fpage>108183</fpage><pub-id pub-id-type="pmid">32360697</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Shenoy</surname><given-names>S.</given-names></name></person-group><article-title>Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality</article-title><source>Inflamm. Res.</source><volume>69</volume><year>2020</year><fpage>1077</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">32767095</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C.-S.</given-names></name><name><surname>Qi</surname><given-names>H.-Y.</given-names></name><name><surname>Boularan</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>N.-N.</given-names></name><name><surname>Abu-Asab</surname><given-names>M.</given-names></name><name><surname>Shelhamer</surname><given-names>J.H.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name></person-group><article-title>SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome</article-title><source>J.&#x000a0;Immunol.</source><volume>193</volume><year>2014</year><fpage>3080</fpage><lpage>3089</lpage><pub-id pub-id-type="pmid">25135833</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C.S.</given-names></name><name><surname>Nabar</surname><given-names>N.R.</given-names></name><name><surname>Huang</surname><given-names>N.N.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name></person-group><article-title>SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes</article-title><source>Cell Death Discov.</source><volume>5</volume><year>2019</year><fpage>101</fpage><pub-id pub-id-type="pmid">31231549</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>D.</given-names></name><name><surname>Mukherjee</surname><given-names>R.</given-names></name><name><surname>Grewe</surname><given-names>D.</given-names></name><name><surname>Bojkova</surname><given-names>D.</given-names></name><name><surname>Baek</surname><given-names>K.</given-names></name><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Schulz</surname><given-names>L.</given-names></name><name><surname>Widera</surname><given-names>M.</given-names></name><name><surname>Mehdipour</surname><given-names>A.R.</given-names></name><name><surname>Tascher</surname><given-names>G.</given-names></name></person-group><article-title>Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2601-5</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Shokri</surname><given-names>S.</given-names></name><name><surname>Mahmoudvand</surname><given-names>S.</given-names></name><name><surname>Taherkhani</surname><given-names>R.</given-names></name><name><surname>Farshadpour</surname><given-names>F.</given-names></name></person-group><article-title>Modulation of the immune response by Middle East respiratory syndrome coronavirus</article-title><source>J.&#x000a0;Cell. Physiol.</source><volume>234</volume><year>2019</year><fpage>2143</fpage><lpage>2151</lpage><pub-id pub-id-type="pmid">30146782</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="book" id="sref101"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K.K.</given-names></name><name><surname>Chaubey</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Suravajhala</surname><given-names>P.</given-names></name></person-group><chapter-title>Decoding SARS-CoV-2 Hijacking of Host Mitochondria in Pathogenesis of COVID-19</chapter-title><year>2020</year><publisher-name>American Physiological Society</publisher-name></element-citation></ref><ref id="bib102"><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>K.L.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Ng</surname><given-names>M.H.</given-names></name><name><surname>Poon</surname><given-names>V.K.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>284</volume><year>2009</year><fpage>16202</fpage><lpage>16209</lpage><pub-id pub-id-type="pmid">19380580</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>K.L.</given-names></name><name><surname>Yuen</surname><given-names>K.S.</given-names></name><name><surname>Casta&#x000f1;o-Rodriguez</surname><given-names>C.</given-names></name><name><surname>Ye</surname><given-names>Z.W.</given-names></name><name><surname>Yeung</surname><given-names>M.L.</given-names></name><name><surname>Fung</surname><given-names>S.Y.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>C.P.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC</article-title><source>FASEB J.</source><volume>33</volume><year>2019</year><fpage>8865</fpage><lpage>8877</lpage><pub-id pub-id-type="pmid">31034780</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Sliter</surname><given-names>D.A.</given-names></name><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Fischer</surname><given-names>T.D.</given-names></name><name><surname>Burman</surname><given-names>J.L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Narendra</surname><given-names>D.P.</given-names></name></person-group><article-title>Parkin and PINK1 mitigate STING-induced inflammation</article-title><source>Nature</source><volume>561</volume><year>2018</year><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">30135585</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Soberanes</surname><given-names>S.</given-names></name><name><surname>Misharin</surname><given-names>A.V.</given-names></name><name><surname>Jairaman</surname><given-names>A.</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L.</given-names></name><name><surname>McQuattie-Pimentel</surname><given-names>A.C.</given-names></name><name><surname>Cho</surname><given-names>T.</given-names></name><name><surname>Hamanaka</surname><given-names>R.B.</given-names></name><name><surname>Meliton</surname><given-names>A.Y.</given-names></name><name><surname>Reyfman</surname><given-names>P.A.</given-names></name><name><surname>Walter</surname><given-names>J.M.</given-names></name></person-group><article-title>Metformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis</article-title><source>Cell Metab.</source><volume>29</volume><year>2019</year><fpage>335</fpage><lpage>347.e5</lpage><pub-id pub-id-type="pmid">30318339</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Somasundaran</surname><given-names>M.</given-names></name><name><surname>Zapp</surname><given-names>M.L.</given-names></name><name><surname>Beattie</surname><given-names>L.K.</given-names></name><name><surname>Pang</surname><given-names>L.</given-names></name><name><surname>Byron</surname><given-names>K.S.</given-names></name><name><surname>Bassell</surname><given-names>G.J.</given-names></name><name><surname>Sullivan</surname><given-names>J.L.</given-names></name><name><surname>Singer</surname><given-names>R.H.</given-names></name></person-group><article-title>Localization of HIV RNA in mitochondria of infected cells: potential role in cytopathogenicity</article-title><source>J.&#x000a0;Cell. Biol.</source><volume>126</volume><year>1994</year><fpage>1353</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">8089170</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Song</surname><given-names>N.</given-names></name><name><surname>Qi</surname><given-names>Q.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Qin</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name></person-group><article-title>MAVS O-GlcNAcylation is essential for host antiviral immunity against lethal RNA viruses</article-title><source>Cell Rep.</source><volume>28</volume><year>2019</year><fpage>2386</fpage><lpage>2396.e5</lpage><pub-id pub-id-type="pmid">31461653</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Nichols</surname><given-names>D.B.</given-names></name><name><surname>Clementz</surname><given-names>M.A.</given-names></name><name><surname>Banach</surname><given-names>B.S.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e30802</fpage><pub-id pub-id-type="pmid">22312431</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>N.</given-names></name><name><surname>Ishihara</surname><given-names>N.</given-names></name><name><surname>Jofuku</surname><given-names>A.</given-names></name><name><surname>Oka</surname><given-names>T.</given-names></name><name><surname>Mihara</surname><given-names>K.</given-names></name></person-group><article-title>Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>282</volume><year>2007</year><fpage>11521</fpage><lpage>11529</lpage><pub-id pub-id-type="pmid">17301055</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.X.</given-names></name><name><surname>Tan</surname><given-names>T.H.</given-names></name><name><surname>Lee</surname><given-names>M.J.</given-names></name><name><surname>Tham</surname><given-names>P.Y.</given-names></name><name><surname>Gunalan</surname><given-names>V.</given-names></name><name><surname>Druce</surname><given-names>J.</given-names></name><name><surname>Birch</surname><given-names>C.</given-names></name><name><surname>Catton</surname><given-names>M.</given-names></name><name><surname>Fu</surname><given-names>N.Y.</given-names></name><name><surname>Yu</surname><given-names>V.C.</given-names></name></person-group><article-title>Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>6346</fpage><lpage>6355</lpage><pub-id pub-id-type="pmid">17428862</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Tatsuta</surname><given-names>T.</given-names></name><name><surname>Langer</surname><given-names>T.</given-names></name></person-group><article-title>Prohibitins</article-title><source>Curr. Biol.</source><volume>27</volume><year>2017</year><fpage>R629</fpage><lpage>R631</lpage><pub-id pub-id-type="pmid">28697355</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>M.Z.</given-names></name><name><surname>Poh</surname><given-names>C.M.</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L.</given-names></name><name><surname>MacAry</surname><given-names>P.A.</given-names></name><name><surname>Ng</surname><given-names>L.F.P.</given-names></name></person-group><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Thoms</surname><given-names>M.</given-names></name><name><surname>Buschauer</surname><given-names>R.</given-names></name><name><surname>Ameismeier</surname><given-names>M.</given-names></name><name><surname>Koepke</surname><given-names>L.</given-names></name><name><surname>Denk</surname><given-names>T.</given-names></name><name><surname>Hirschenberger</surname><given-names>M.</given-names></name><name><surname>Kratzat</surname><given-names>H.</given-names></name><name><surname>Hayn</surname><given-names>M.</given-names></name><name><surname>Mackens-Kiani</surname><given-names>T.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name></person-group><article-title>Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">32680882</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Tiku</surname><given-names>V.</given-names></name><name><surname>Tan</surname><given-names>M.-W.</given-names></name><name><surname>Dikic</surname><given-names>I.</given-names></name></person-group><article-title>Mitochondrial functions in infection and immunity</article-title><source>Trends Cell Biol.</source><volume>30</volume><year>2020</year><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">32200805</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>A.L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon</article-title><source>Curr. Opin. Virol.</source><volume>2</volume><year>2012</year><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">22572391</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Tyrrell</surname><given-names>D.J.</given-names></name><name><surname>Bharadwaj</surname><given-names>M.S.</given-names></name><name><surname>Jorgensen</surname><given-names>M.J.</given-names></name><name><surname>Register</surname><given-names>T.C.</given-names></name><name><surname>Molina</surname><given-names>A.J.A.</given-names></name></person-group><article-title>Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: implications for a minimally invasive biomarker of mitochondrial health</article-title><source>Redox Biol.</source><volume>10</volume><year>2016</year><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">27693859</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Vabret</surname><given-names>N.</given-names></name><name><surname>Britton</surname><given-names>G.J.</given-names></name><name><surname>Gruber</surname><given-names>C.</given-names></name><name><surname>Hegde</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kuksin</surname><given-names>M.</given-names></name><name><surname>Levantovsky</surname><given-names>R.</given-names></name><name><surname>Malle</surname><given-names>L.</given-names></name><name><surname>Moreira</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>M.D.</given-names></name></person-group><article-title>Immunology of COVID-19: current state of the science</article-title><source>Immunity</source><volume>52</volume><year>2020</year><fpage>910</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">32505227</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z.T.</given-names></name><name><surname>Grant</surname><given-names>A.</given-names></name><name><surname>Manicassamy</surname><given-names>B.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential</article-title><source>J.&#x000a0;Virol.</source><volume>86</volume><year>2012</year><fpage>8359</fpage><lpage>8366</lpage><pub-id pub-id-type="pmid">22674996</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis</article-title><source>Aging (Albany NY)</source><volume>12</volume><year>2020</year><fpage>6049</fpage><pub-id pub-id-type="pmid">32267833</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Wathelet</surname><given-names>M.G.</given-names></name><name><surname>Orr</surname><given-names>M.</given-names></name><name><surname>Frieman</surname><given-names>M.B.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>11620</fpage><lpage>11633</lpage><pub-id pub-id-type="pmid">17715225</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>S.E.</given-names></name><name><surname>Sena</surname><given-names>L.A.</given-names></name><name><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Mitochondria in the regulation of innate and adaptive immunity</article-title><source>Immunity</source><volume>42</volume><year>2015</year><fpage>406</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">25786173</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>West</surname><given-names>A.P.</given-names></name><name><surname>Khoury-Hanold</surname><given-names>W.</given-names></name><name><surname>Staron</surname><given-names>M.</given-names></name><name><surname>Tal</surname><given-names>M.C.</given-names></name><name><surname>Pineda</surname><given-names>C.M.</given-names></name><name><surname>Lang</surname><given-names>S.M.</given-names></name><name><surname>Bestwick</surname><given-names>M.</given-names></name><name><surname>Duguay</surname><given-names>B.A.</given-names></name><name><surname>Raimundo</surname><given-names>N.</given-names></name><name><surname>MacDuff</surname><given-names>D.A.</given-names></name></person-group><article-title>Mitochondrial DNA stress primes the antiviral innate immune response</article-title><source>Nature</source><volume>520</volume><year>2015</year><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">25642965</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>West</surname><given-names>A.P.</given-names></name><name><surname>Shadel</surname><given-names>G.S.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name></person-group><article-title>Mitochondria in innate immune responses</article-title><source>Nat. Rev. Immunol.</source><volume>11</volume><year>2011</year><fpage>389</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">21597473</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K.E.</given-names></name><name><surname>Fazal</surname><given-names>F.M.</given-names></name><name><surname>Parker</surname><given-names>K.R.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name></person-group><article-title>RNA-GPS predicts SARS-CoV-2 RNA residency to host mitochondria and nucleolus</article-title><source>Cell Syst.</source><volume>11</volume><year>2020</year><fpage>102</fpage><lpage>108.e3</lpage><pub-id pub-id-type="pmid">32673562</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Yi</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Lemon</surname><given-names>S.M.</given-names></name></person-group><article-title>Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor</article-title><source>Proc. Natl. Acad. Sci. U S A.</source><volume>104</volume><year>2007</year><fpage>7253</fpage><lpage>7258</lpage><pub-id pub-id-type="pmid">17438296</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Kinoshita</surname><given-names>D.</given-names></name><name><surname>Yaku</surname><given-names>K.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>The microRNAs miR-302b and miR-372 regulate mitochondrial metabolism via the SLC25A12 transporter, which controls MAVS-mediated antiviral innate immunity</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>295</volume><year>2020</year><fpage>444</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">31767682</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Oshiumi</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Ishihara</surname><given-names>N.</given-names></name><name><surname>Yanagi</surname><given-names>Y.</given-names></name><name><surname>Seya</surname><given-names>T.</given-names></name><name><surname>Kawabata</surname><given-names>S.-i.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>Mitofusin 2 inhibits mitochondrial antiviral signaling</article-title><source>Sci. Signal.</source><volume>2</volume><year>2009</year><fpage>ra47</fpage><pub-id pub-id-type="pmid">19690333</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Yoshinaka</surname><given-names>T.</given-names></name><name><surname>Kosako</surname><given-names>H.</given-names></name><name><surname>Yoshizumi</surname><given-names>T.</given-names></name><name><surname>Furukawa</surname><given-names>R.</given-names></name><name><surname>Hirano</surname><given-names>Y.</given-names></name><name><surname>Kuge</surname><given-names>O.</given-names></name><name><surname>Tamada</surname><given-names>T.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>Structural basis of mitochondrial scaffolds by prohibitin complexes: Insight into a role of the coiled-coil region</article-title><source>iScience</source><volume>19</volume><year>2019</year><fpage>1065</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">31522117</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Yoshizumi</surname><given-names>T.</given-names></name><name><surname>Ichinohe</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>O.</given-names></name><name><surname>Otera</surname><given-names>H.</given-names></name><name><surname>Kawabata</surname><given-names>S.-i.</given-names></name><name><surname>Mihara</surname><given-names>K.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>Influenza A virus protein PB1-F2 translocates into mitochondria via Tom40 channels and impairs innate immunity</article-title><source>Nat. Commun.</source><volume>5</volume><year>2014</year><fpage>4713</fpage><pub-id pub-id-type="pmid">25140902</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Yoshizumi</surname><given-names>T.</given-names></name><name><surname>Imamura</surname><given-names>H.</given-names></name><name><surname>Taku</surname><given-names>T.</given-names></name><name><surname>Kuroki</surname><given-names>T.</given-names></name><name><surname>Kawaguchi</surname><given-names>A.</given-names></name><name><surname>Ishikawa</surname><given-names>K.</given-names></name><name><surname>Nakada</surname><given-names>K.</given-names></name><name><surname>Koshiba</surname><given-names>T.</given-names></name></person-group><article-title>RLR-mediated antiviral innate immunity requires oxidative phosphorylation activity</article-title><source>Scientific Rep.</source><volume>7</volume><year>2017</year><fpage>5379</fpage></element-citation></ref><ref id="bib131"><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>Y.</given-names></name><name><surname>Nabar</surname><given-names>N.R.</given-names></name><name><surname>Shi</surname><given-names>C.-S.</given-names></name><name><surname>Kamenyeva</surname><given-names>O.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Hwang</surname><given-names>I.-Y.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name></person-group><article-title>SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death</article-title><source>Cell Death Dis.</source><volume>9</volume><year>2018</year><fpage>904</fpage><pub-id pub-id-type="pmid">30185776</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Zas&#x00142;ona</surname><given-names>Z.</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>L.A.</given-names></name></person-group><article-title>Cytokine-like roles for metabolites in immunity</article-title><source>Mol. Cell</source><volume>78</volume><year>2020</year><fpage>814</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">32333837</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>Z.-G.</given-names></name><name><surname>Tu</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name></person-group><article-title>Lactate is a natural suppressor of RLR signaling by targeting MAVS</article-title><source>Cell</source><volume>178</volume><year>2019</year><fpage>176</fpage><lpage>189.e15</lpage><pub-id pub-id-type="pmid">31155231</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>This work was partly supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001691</institution-id><institution>JSPS</institution></institution-wrap></funding-source> KAKENHI Grant 20H04914 (to T.K.).</p><sec id="sec7"><title>Author Contributions</title><p id="p0250">Conceptualization, J.B.; Methodology, J.B., G.C., A.O., T.K., and G.P.M.; Writing &#x02013; Original Draft, J.B.; Writing &#x02013; Review and Editing, J.B., G.C., A.O., T.K., and G.P.M.</p></sec></ack></back></article>